

Notice: This material is protected by copyright law and may only be used for personal, non-commercial and educational use. It may not be copied or shared with others.

University of Notre Dame Interlibrary Loan



ILLiad TN: 834370

Borrower: RAPID:UCW

Lending String:

Patron:

Journal Title: Reviews of physiology, biochemistry
and pharmacology

Volume: 166 **Issue:**
Month/Year: 2014**Pages:** 43-95

Article Author: Goodman, C

Article Title: The role of mTORC1 in regulating
protein synthesis and skeletal muscle mass in
response to various mechanical stimuli

Imprint:

ILL Number: -9010493

Call #: QP 1 .Er38 2014

Location: LL

Mail

Charge
Maxcost:

Shipping Address:
University of Connecticut
N/A

Odyssey: 206.107.43.160

- Wang W, Wyckoff JB, Goswami S, Wang Y, Sidani M, Segall JE, Condeelis JS (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. *Cancer Res* 67(8):3505–3511
- Watanabe S, Ando Y, Yasuda S, Hosoya H, Watanabe N, Ishizaki T, Narumiya S (2008) mDia2 induces the actin scaffold for the contractile ring and stabilizes its position during cytokinesis in NIH 3T3 cells. *Mol Biol Cell* 19(5):2328–2338
- Wu C, Asokan SB, Berginski ME, Haynes EM, Sharpless NE, Griffith JD, Gomez SM, Bear JE (2012) Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. *Cell* 148(5):973–987
- Yamaguchi H, Lorenz M, Kempia S, Sarmiento C, Coniglio S, Symons M, Segall J, Eddy R, Miki H, Takenawa T, Condeelis J (2005) Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. *J Cell Biol* 168(3):441–452
- Yang C, Czech L, Gerboth S, Kojima S, Scita G, Svitkina T (2007) Novel roles of formin mDia2 in lamellipodia and filopodia formation in motile cells. *PLoS Biol* 5(11):e317
- Yu X, Zech T, McDonald L, Gonzalez EG, Li A, Macpherson I, Schwarz JP, Spence H, Futó K, Timpson P, Nixon C, Ma Y, Anton IM, Visegrády B, Insall RH, Oien K, Blyth K, Normán JC, Machesky LM (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. *J Cell Biol*. doi:10.1083/jcb.201203025
- Zhu X-L, Liang L, Ding Y-Q (2008) Overexpression of FMNL2 is closely related to metastasis of colorectal cancer. *Int J Colorectal Dis* 23(11):1041–1047
- Zuchero JB, Coutts AS, Quinlan ME, Thangue NB, Mullins RD (2009) p53-cofactor JMY is a multifunctional actin nucleation factor. *Nat Cell Biol* 11(4):451–459

The Role of mTORC1 in Regulating Protein Synthesis and Skeletal Muscle Mass in Response to Various Mechanical Stimuli

Craig A. Goodman

Abstract Skeletal muscle plays a fundamental role in mobility, disease prevention, and quality of life. Skeletal muscle mass is, in part, determined by the rates of protein synthesis, and mechanical loading is a major regulator of protein synthesis and skeletal muscle mass. The mammalian/mechanistic target of rapamycin (mTOR), found in the multi-protein complex, mTORC1, is proposed to play an essential role in the regulation of protein synthesis and skeletal muscle mass. The purpose of this review is to examine the function of mTORC1 in relation to protein synthesis and cell growth, the current evidence from rodent and human studies for the activation of mTORC1 signaling by different types of mechanical stimuli, whether mTORC1 signaling is necessary for changes in protein synthesis and skeletal muscle mass that occur in response to different types of mechanical stimuli, and the proposed molecular signaling mechanisms that may be responsible for the mechanical activation of mTORC1 signaling.

Contents

| | | |
|-----|---|----|
| 1 | Introduction | 44 |
| 2 | mTOR and mTORC1 | 46 |
| 2.1 | A Brief History of Rapamycin, mTOR, and mTORC1 | 46 |
| 2.2 | The Cellular Location of mTOR and mTORC1 | 48 |
| 2.3 | Protein Synthesis-Related mTORC1 Signaling Targets | 50 |
| 2.4 | New-Generation ATP-Competitive mTOR Inhibitors and Their Implications for Understanding mTORC1-Mediated Processes | 57 |
| 3 | The Role of mTORC1 in the Regulation of Mechanical Stimuli-Induced and Basal Rates of Protein Synthesis | 58 |
| 3.1 | Evidence for the Role of mTORC1 in the Regulation of Muscle Mass and Protein Synthesis in Response to Increased Mechanical Loading or Resistance Exercise ... | 58 |
| 3.2 | Evidence for the Role of mTORC1 Signaling in the Regulation of Protein Synthesis in Recovery from Acute Endurance Exercise | 62 |

C.A. Goodman (✉)

Department of Comparative Biosciences, School of Veterinary Medicine,
University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA
e-mail: cgoodman2@wisc.edu

| | | |
|-----|---|----|
| 3.3 | Evidence for the Activation of mTORC1 Signaling by High-Intensity Sprint Exercise | 64 |
| 3.4 | Does mTORC1 Signaling Regulate Basal Protein Synthesis and Resting Skeletal Muscle Mass? | 65 |
| 4 | Potential Activators of mTORC1 Signaling Induced by Mechanical Overload or Resistance Exercise | 67 |
| 4.1 | Insulin-Like Growth Factor 1 (IGF-1) | 67 |
| 4.2 | Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) | 70 |
| 4.3 | Phosphatidic Acid (PA) | 71 |
| 4.4 | Tuberin (TSC2) Translocation and Ras Homologue Expressed in the Brain (Rheb) GTP-Loading Status | 72 |
| 4.5 | Amino Acids | 74 |
| 4.6 | Peroxyinitrite-Induced Calcium Release | 75 |
| 5 | Conclusion | 77 |
| | References | 78 |

1 Introduction

Skeletal muscle plays fundamental roles in the body, including the generation of limb and trunk movements and the control of breathing. Furthermore, due to the relatively large proportion of the body that is made up of skeletal muscle (~45 %), skeletal muscle also plays an important role in the regulation of whole-body metabolism (Lee et al. 2000; Izumiya et al. 2008). Thus, the maintenance of skeletal muscle mass is essential for mobility, disease prevention, and quality of life (Seguin and Nelson 2003; Lynch 2004; Srikanthan and Karlamangla 2011). For these reasons, a thorough understanding of the molecular mechanisms that regulate skeletal muscle mass is crucial to the development of effective exercise programs and potential pharmacological interventions aimed at preventing the loss of, or increasing, skeletal muscle mass.

Skeletal muscle mass is ultimately determined by the net difference in the rates of protein degradation and protein synthesis (Goodman et al. 2011c). For example, a net decrease in protein synthesis and/or a net increase in protein degradation leads to a reduction in muscle mass, otherwise known as muscle atrophy. Conversely, a net increase in protein synthesis and/or a net decrease in protein degradation leads to an increase in muscle mass, known as muscle hypertrophy. Importantly, the rates of protein synthesis and degradation can change quite rapidly, and these changes can be evoked by changes in a variety of stimuli including nutrients, neural activity, cytokines, growth factors, hormones, and mechanical loading (Bodine 2006; Frost and Lang 2007; Sandri 2008).

Mechanical loading is known to be a major regulator of skeletal muscle mass, with an increase in mechanical loading resulting in muscle hypertrophy and a decrease in mechanical loading resulting in muscle atrophy [for reviews, see (Goldberg et al. 1975; Adams and Bamman 2012)]. Furthermore, these mechanical load-induced changes in muscle mass are associated with changes in protein synthesis. For example, increased mechanical load-induced muscle hypertrophy is associated

with an increase in protein synthesis, while mechanical unloading-induced muscle atrophy is associated with a decrease in protein synthesis (Goldberg 1968a; Vandenburg 1987; Adams and Bamman 2012). Although changes in protein synthesis appear to play a central role in the mechanical regulation of skeletal muscle mass, the molecular mechanisms through which changes in mechanical loading regulate protein synthesis, and thus muscle mass, remain to be fully determined. Furthermore, it is unclear whether different types of mechanical loading regulate protein synthesis and muscle mass in a similar or distinct manner.

Over the last decade, it has become apparent that the protein kinase known as mTOR (the mammalian/mechanistic target of rapamycin), which is found in the multi-protein complex called mTORC1, plays a fundamental role in the regulation of skeletal muscle mass (Sandri 2008; Frost and Lang 2011). In addition, mTORC1 has been identified as a master regulator of mRNA translation, and thus protein synthesis, with the potential to regulate both translational efficiency (i.e., the rate of mRNA translation) and translational capacity (i.e., the number of ribosomes) [for a review, see (Mahoney et al. 2009)]. To date, however, the necessity of mTORC1 signaling in the regulation of protein synthesis and skeletal muscle mass in response to different types of mechanical stimuli remains to be fully determined. Furthermore, the molecular mechanisms that regulate mTORC1 signaling in skeletal muscle in response to different mechanical loading paradigms are only beginning to be defined.

Thus, the purposes of this review are to: (1) briefly describe the discovery of mTOR and mTORC1, the cellular location of mTOR/mTORC1, and two of mTORC1's direct, and most studied, protein synthesis-related targets, p70^{S6K1} and 4E-BP1; (2) briefly describe another potential mTORC1-regulated and protein synthesis-related molecule, eIF2B ϵ ; (3) detail current evidence from rodent and human studies for the role of mTORC1 signaling in mechanical overload/resistance exercise-induced increases in protein synthesis and muscle mass; (4) summarize evidence from animal and human studies regarding whether mTORC1 signaling is also activated by acute bouts of endurance and sprint exercise; (5) examine the available evidence for a role of mTORC1 in the regulation of basal/resting protein synthesis and muscle mass; and (6) examine the main putative upstream molecular signaling mechanisms that are proposed to play a role in the activation of mTORC1 signaling in response to mechanical overload/resistance exercise.

Before beginning, it is important to note that while this review focuses on mTOR and mTORC1, other signaling mechanisms also play important roles in the regulation of protein synthesis and muscle mass [for recent reviews, see (Lynch and Ryall 2008; Glass 2010; Huang et al. 2011; Lee and MacLean 2011; McCarthy 2011; Phillips et al. 2012; Schiaffino and Mammucari 2011; Adams and Bamman 2012; Berdeaux and Stewart 2012; Dubois et al. 2012; Piccirillo et al. 2013)]. Furthermore, it should also be recognized that the activation of mTORC1 signaling could, in part, regulate skeletal muscle mass via the inhibition of autophagy-mediated protein degradation (Jung et al. 2010; Sandri 2013). Finally, due to space limitations, this review will not give a specific overview of the molecular regulation of protein synthesis (i.e., translation initiation, elongation and termination, and ribosome biogenesis);

however, the interested reader is directed to the following recent reviews: Mayer and Grummt 2006; Moss et al. 2007; Kelen et al. 2009; Mahoney et al. 2009; Topisirovic et al. 2011; and Hinnebusch and Lorsch 2012.

2 mTOR and mTORC1

2.1 A Brief History of Rapamycin, mTOR, and mTORC1

In 1965, an antifungal/antibiotic compound produced by microbes (*Streptomyces hygroscopicus*) found in soil from the island of Rapa Nui (Easter Island) was isolated and subsequently named rapamycin (Sehgal et al. 1975; Vezina et al. 1975; Baker et al. 1978). Later, rapamycin was found to also have immunosuppressant properties that required its binding to FK506-binding protein 12 (FKBP12) (Harding et al. 1989; Sehgal 2003). The mechanism behind this rapamycin-induced immunosuppression was shown to be via the inhibition of T cell proliferation (Dumont et al. 1990) and, specifically, the blocking of the transition from the G1 to the S phase of the cell cycle (Heitman et al. 1991). Rapamycin-induced cell cycle arrest was also found to be associated with the inhibition of the phosphorylation of the mitogen-activated 70 kDa ribosomal protein S6 kinase (p70^{S6K}) (Banerjee et al. 1990; Chung et al. 1992; Kuo et al. 1992; Price et al. 1992), indicating that rapamycin might suppress growth, not only by inhibiting cell proliferation but also by inhibiting mitogen-induced changes in cell size. In 1991, the growth-related targets of rapamycin were identified in yeast (*Saccharomyces cerevisiae*) and named the targets of rapamycin 1 and 2 (TOR1 and TOR2) (Heitman et al. 1991). Subsequent sequencing of TOR1 and TOR2 revealed that they were highly homologous to phosphoinositide lipid kinases but were later found to be serine/threonine protein kinases. By 1994, a single mammalian ortholog of the yeast TOR genes was discovered by several laboratories and given the names rapamycin target (RAPT1) (Chiu et al. 1994), FKBP-rapamycin-associated protein (FRAP) (Brown et al. 1994), and rapamycin and FKBP target 1 (RAFT1) (Sabatini et al. 1994). These names were later standardized to the mammalian target of rapamycin (mTOR) (Sabers et al. 1995); however, in 2009 the definition of the mTOR gene name was officially changed by the HUGO Gene Nomenclature Committee to the mechanistic target of rapamycin in an attempt to make the name more applicable across all species (Hall 2013).

Structurally, mTOR was shown to be a relatively large protein consisting of 2,549 amino acids, with a predicted molecular mass of 289 kDa (Sabers et al. 1995). Several important domains were identified in mTOR, including a C-terminal kinase domain, which is responsible for autophosphorylation and phosphorylation of downstream targets (Brown et al. 1995), and the FKBP12-rapamycin-binding (FRB) domain (Chen et al. 1995; Jungwon et al. 1996), as well as multiple N-terminal HEAT (Huntingtin, elongation factor 3, regulatory A subunit of PP2A, and Tor1)

motifs that are thought to mediate protein-protein interactions (Perry and Kleckner 2003). Evidence that mTOR did indeed participate in protein-protein interactions came from size exclusion chromatography experiments that showed that mTOR had an apparent molecular mass of ~1–2 MDa instead of 289 kDa (Fang et al. 2001; Kim et al. 2002). These reports strongly suggested the presence of other mTOR-associated proteins and, thus, the potential for mTOR to be part of a multicomponent protein complex. Indeed, in 2002, mTOR was reported to associate with a 150 kDa protein called the regulatory associated protein of mTOR (Raptor) (Hara et al. 2002; Kim et al. 2002). As well as binding to mTOR, Raptor was found to directly interact with known mTOR substrates, such as 4E-BP1 and p70^{S6K}, via a short amino acid sequence called the TOS (mTOR Signaling) motif (Schalm and Blenis 2002; Nojima et al. 2003; Schalm et al. 2003). Around the same time, mTOR was also found to bind a 36 kDa protein called mammalian lethal with SEC13 protein 8 (mLST8; aka G-protein β -subunit-like protein, G β L), which functioned as a positive regulator of mTOR kinase activity (Loewith et al. 2002; Kim et al. 2003).

In 2004, the story of mTOR became significantly more complex with the identification of another mTOR-binding protein named Rictor (rapamycin-insensitive companion of mTOR) which had the effect of rendering mTOR essentially resistant to the inhibitory effect of rapamycin (Dos et al. 2004; Jacinto et al. 2004). Thus, now there were two mTOR complexes: the Raptor-associated rapamycin-sensitive mTOR complex 1 (mTORC1) and the Rictor-associated rapamycin-insensitive mTOR complex 2 (mTORC2) (Dos et al. 2004; Jacinto et al. 2004). Like mTORC1, mTORC2 was associated with mLST8 but was later shown to contain other distinct proteins such as mSIN1 (mammalian stress-activated protein kinase interacting protein 1) (Frias et al. 2006) and Protor-1 (protein observed with Rictor-1) (Pearce et al. 2007). Subsequent studies found that mTORC2 also had different downstream substrates than mTORC1, including members of the AGC kinase family, protein kinase B (PKB; aka Akt) (Sarbasov et al. 2005), protein kinase C (PKC) (Guertin et al. 2006), and serum- and glucocorticoid-induced protein kinase 1 (SGK1) (García-Martínez and Alessi 2008). Furthermore, mTORC2 was shown to regulate processes distinct from mTORC1, such as actin cytoskeleton organization (Jacinto et al. 2004) and cell proliferation and survival (Goncharova et al. 2011). Although initially shown to be rapamycin resistant, more recent studies have shown that with prolonged exposure to rapamycin, the assembly of mTORC2, and thus mTORC2 signaling, can be inhibited, including in skeletal muscle (Sarbasov et al. 2006; Lamming et al. 2012).

In 2007, a previously identified insulin-sensitive protein called PRAS40 (proline-rich Akt substrate of 40 kDa) (Kovacina et al. 2003) was found to be another component of mTORC1 (Haar et al. 2007; Sancak et al. 2007; Wang et al. 2007). PRAS40 was shown to bind to Raptor via a modified TOS motif and inhibit mTORC1 kinase activity, possibly by inhibiting substrate binding to Raptor (Haar et al. 2007; Sancak et al. 2007; Wang et al. 2007). Upon stimulation by insulin, Akt-induced phosphorylation of PRAS40 resulted in its dissociation from mTORC1 and an increase in mTORC1 signaling (Haar et al. 2007; Sancak et al. 2007;

Wang et al. 2007). In addition, it was shown that activated mTORC1 could also phosphorylate PRAS40, thus further relieving PRAS40-mediated repression of mTORC1 signaling (Oshiro et al. 2007; Wang et al. 2008). Finally, in 2009, mTOR was found to associate with a 48 kDa protein named Deptor (dishevelled, egl-10, pleckstrin domain protein interacting with mTOR), which inhibited both mTORC1 and mTORC2 signaling (Peterson et al. 2009). Later, it was shown that activated mTORC1 and mTORC2 could phosphorylate Deptor, leading to its ubiquitination by the E3 ligase complex SCF β TrCP and subsequent degradation by the ubiquitin proteasome system (Duan et al. 2011; Gao et al. 2011; Zhao et al. 2011). Thus, activated mTORC1 and mTORC2 could mediate the degradation of Deptor and, in effect, create a positive feedback loop that further enhanced mTORC1 and mTORC2 signaling.

In summary, the unearthing of rapamycin led to the discovery of mTOR and has facilitated huge progress in our understanding of the regulation of cell growth and proliferation. Moreover, the identification of the accessory proteins that make up the rapamycin-sensitive mTORC1 (see Fig. 1) and the largely rapamycin-insensitive mTORC2 has further expanded our understanding of the roles mTOR plays in cell biology. It remains to be determined whether more mTOR-associated proteins will be discovered in the future, or even new mTOR complexes, which may further expand our understanding of cellular growth. Indeed, there is already speculation regarding the existence of an mTORC3 (e.g., (Alayev and Holz 2013)). Furthermore, future studies may also lead to the discovery of new functions and targets for mTOR that is free from any other associated proteins.

2.2 The Cellular Location of mTOR and mTORC1

Early non-muscle cell fractionation studies identified mTOR as a cytoplasmic protein that was associated with intracellular membranes (Withers et al. 1997; Sabatini et al. 1999). Consistent with these studies, mTOR has been shown to associate with the endoplasmic reticulum (ER) and Golgi apparatus in a variety of cell lines (Drenan et al. 2004). Another pool of mTOR has been found to be associated with the outer mitochondrial membrane, suggesting a potential role in the regulation of energy metabolism (Desai et al. 2002). Immunohistochemical studies have shown that mTOR is dispersed through the cytoplasm and, under certain conditions, could also adopt a more punctate appearance, perhaps indicating that certain conditions can induce mTOR translocation (Sabatini et al. 1999). A small amount of mTOR has also been found in the nucleus, and mTOR has been shown to shuttle between the cytoplasm and nucleus (Kim and Chen 2000; Bachmann et al. 2006). Further support for a nuclear pool of mTOR comes from studies showing an association between mTOR and the promoters of RNA polymerases I to III and other various transcription factors, including some involved in mitochondrial biogenesis (Cunningham et al. 2007; Kantidakis et al. 2010; Shor et al. 2010; Tsang et al. 2010).




Fig. 1 A summary of the protein components of mTORC1 and mTORC1's protein synthesis-related signaling targets. mTORC1 (mTOR complex 1) is composed of mTOR (the mammalian/mechanistic target of rapamycin), Raptor (regulatory associated protein of mTOR), mLST8 (mammalian lethal with SEC13 protein 8), Deptor (dishevelled, egl-10, pleckstrin domain protein interacting with mTOR), and PRAS40 (proline-rich Akt substrate of 40 kDa). mTORC1 signaling can be inhibited by the rapamycin/FKBP12 (FK506-binding protein 12) complex and by PRAS40 and Deptor. Two of mTORC1's most studied protein synthesis-related targets are p70^{S6K1} (ribosomal protein S6 p70 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1). p70^{S6K1} is proposed to regulate protein synthesis, in part, by the direct phosphorylation of rpS6 (ribosomal protein S6), eIF4B (eukaryotic initiation factor 4B), eEF2 kinase (eukaryotic elongation factor kinase), PDCD4 (programmed cell death protein 4), and UBF (upstream binding factor) and, in part, by regulating the expression ribosome biogenesis (RB)-associated transcription factors and pyrimidine nucleotide synthesis. 4E-BP1 is proposed to regulate protein synthesis by inhibiting the interaction between the 7-mG (5'-7-methylguanosine) cap-bound eIF4E (eukaryotic initiation factor 4E) and eIF4G. mTORC1-induced phosphorylation of 4E-BP1 is proposed to relieve 4E-BP1's repression of eIF4E binding to eIF4G, leading to increased global cap-dependent translation initiation, and to increase the specific translation of mRNAs with highly structured 5'-untranslated regions (or "weak" mRNAs) and mRNAs that contain a 5'-tract of pyrimidines (5'TOP mRNAs). mTORC1 signaling has also been shown to increase the abundance of eIF2Bε, although the exact mechanism remains to be determined. Combined, mTORC1 signaling leads to an increase in cap-dependent translation initiation, translation elongation, and ribosome biogenesis, which, in turn, leads to an increase in protein synthesis and, potentially, cell growth.

While these studies clearly indicate that mTOR is found in different cellular locations, they do not identify whether the mTOR being detected is part of mTORC1. More recent studies have, however, shed light on the possible locations of mTORC1. For instance, mTOR and Raptor are found in mitochondrial fractions and, interestingly, rapamycin treatment has been shown to significantly alter the mitochondrial phosphoproteome (Schieke et al. 2006). Raptor has also been found in the nucleus, suggesting the presence of nuclear mTORC1 (Rosner and Hengstschläger 2008). Moreover, mTORC1 has been found at the ER and has been proposed to play a role in ER stress signaling (Ramirez-Rangel et al. 2011; Appenzeller-Herzog and Hall 2012). Recent groundbreaking work has also shown that upon amino acid stimulation, mTOR and Raptor translocate to late endosomal/lysosomal (LEL) membrane structures where mTORC1 signaling is activated to transmit amino acid-induced anabolic signaling (Sancak et al. 2010).

To date, there is very little information regarding the cellular location of mTOR/mTORC1 in skeletal muscle cells. Recent work, however, has identified a pool of mTOR that is associated with LEL structures in mouse skeletal muscle. Moreover, this association was increased in response to mechanical activation (i.e., eccentric contractions), suggesting a possible mechanically induced translocation event (Jacobs et al. 2013b). It remains to be determined whether this LEL-associated mTOR is part of mTORC1 and whether the increased association with the LEL plays a significant role in the mechanical activation of mTORC1 signaling.

Overall, in non-muscle cells mTOR and mTORC1 are found in several different cellular compartments, which probably reflects their diverse and important range of functions within the cell (i.e., stress and nutrient sensing, gene transcription, energy metabolism, and protein degradation and synthesis). While some progress has been made, much more research is required to expand our understanding of the location/function relationship of mTORC1 in skeletal muscle and whether a specific pool of mTORC1 is activated by mechanical stimuli.

2.3 Protein Synthesis-Related mTORC1 Signaling Targets

To date, the two most studied direct targets of mTORC1 are the ribosomal protein S6 p70 kinase 1 (p70^{S6K1}) and the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Both of these mTORC1 targets are involved in the regulation of protein synthesis via their influence on translation initiation and elongation and ribosome biogenesis (Fig. 1). This section will briefly review the identification of p70^{S6K1} and 4E-BP1 and how mTORC1 is proposed to regulate these two proteins and their downstream protein synthesis-related targets. Another potential protein synthesis-related target of mTORC1 signaling, which has received significantly less attention, is the abundance of the eukaryotic initiation factor 2B subunit e (eIF2Be). Thus, this section will also briefly describe the role of eIF2Be in the regulation of protein synthesis and its possible regulation by mTORC1 in skeletal muscle.

2.3.1 Ribosomal Protein S6 p70 Kinase 1 (p70^{S6K1})

In the late 1970s, insulin and the insulin-like growth factor were shown to stimulate the phosphorylation of the 40S ribosomal subunit-associated ribosome S6 protein (rpS6) in fibroblasts and pre-adipocytes (Haselbacher et al. 1979; Smith et al. 1979). Almost a decade later, a 70 kDa serine/threonine protein kinase was identified as a kinase that phosphorylated rpS6 and, as such, was named the p70 ribosomal protein S6 kinase (p70^{S6K}) but later changed to p70^{S6K1} (Banerjee et al. 1990; Price et al. 1990; Shima et al. 1998). Similar to rpS6, p70^{S6K1} was also found to be phosphorylated in response to insulin stimulation and, importantly, rapamycin was shown to inhibit insulin-stimulated p70^{S6K1} phosphorylation (Chung et al. 1992; Kuo et al. 1992; Price et al. 1992). A search for the specific rapamycin-sensitive phosphorylation site(s) on p70^{S6K1} revealed that, although the phosphorylation of the T389, T229, S404, and S411 residues was inhibited by rapamycin, the loss of T389 phosphorylation was most closely associated with the loss of p70^{S6K1} activation (Pearson et al. 1995; Dennis et al. 1996). Indeed, the mutation of T389 to a non-phosphorylatable alanine residue (A389) completely abolished p70^{S6K1} activity, providing further evidence that the phosphorylation of T389 by mTORC1 was a major event in the activation of p70^{S6K1} (Pearson et al. 1995) [Note: It was later found that T229 phosphorylation by PDK1 (phosphoinositide-dependent kinase 1) was also required for full activation of p70^{S6K1} activity (Alessi et al. 1998; Pullen et al. 1998)]. Combined, these data showed that the phosphorylation of the T389 residue is critical for p70^{S6K1} function and that the T389 residue is a major rapamycin-sensitive phosphorylation site on p70^{S6K1} and, thus, a major target of mTORC1 signaling. Because of the role of mTORC1 in the phosphorylation of p70^{S6K1}, combined with the relative ease of assessing T389 phosphorylation via a Western blot analysis, p70^{S6K1} T389 phosphorylation remains one of the most commonly used readouts of changes in mTORC1 signaling in human, animal, and cell culture studies that investigate the mechanical activation of mTORC1 signaling in skeletal muscle. Interestingly, despite evidence that p70^{S6K1} may play an important role in mTORC1-mediated muscle cell hypertrophy in response to IGF-1 and nutrients (Ohanna et al. 2005; Aguilar et al. 2007; Mieulet et al. 2007), it still remains to be determined whether mTORC1-mediated p70^{S6K1} T389 phosphorylation is in fact necessary for mechanically induced increases in skeletal muscle protein synthesis and muscle mass.

2.3.2 p70^{S6K1} Protein Synthesis-Related Signaling Targets

p70^{S6K1} has the potential to regulate cell size, in part, due to its ability to regulate several factors involved in translation initiation and, thus, protein synthesis. For example, p70^{S6K1} can phosphorylate the eukaryotic translation initiation factor 4B (eIF4B) on the S422 residue, which leads to an increased interaction with the

eIF3/preinitiation complex and the recruitment of the RNA helicase eIF4A (Holz et al. 2005; Shahbazian et al. 2006). Indeed, it has been shown that an S422D phosphomimetic mutant of eIF4B is sufficient to increase protein synthesis (Holz et al. 2005). Another $p70^{S6K1}$ target is the eukaryotic elongation factor 2 kinase (eEF2 kinase). eEF2 kinase phosphorylates eEF2 on the T56 residue, leading to its inhibition and the repression of the translation elongation process (Wang et al. 2001). $p70^{S6K1}$ inactivates eEF2 kinase by phosphorylating its S366 residue and relieving eEF2 kinase-induced inhibition of translation elongation (Wang et al. 2001). More recent evidence suggests that eEF2 kinase S366 phosphorylation may also be regulated in an mTORC1-dependent but $p70^{S6K1}$ -independent manner in skeletal muscle cells (Mieulet et al. 2007). A third $p70^{S6K1}$ target with the potential to regulate protein synthesis is the tumor suppressor, the programmed cell death protein 4 (PDCD4). PDCD4 binds to the RNA helicase eIF4A and inhibits translation initiation (Suzuki et al. 2008; Loh et al. 2009). $p70^{S6K1}$ -induced phosphorylation of PDCD4 on the S67 residue has been shown to lead to the degradation of PDCD4 by the ubiquitin proteasome system, resulting in an increase in protein synthesis (Dorrello et al. 2006; Zargar et al. 2011).

As mentioned above, another target of $p70^{S6K1}$ with the potential to regulate protein synthesis and cell size is rpS6. rpS6 is predominantly phosphorylated on five residues in response to serum stimulation: S235, S236, S240, S244, and S247 (Krieg et al. 1988; Ferrari et al. 1991; Bandi et al. 1993). As the phosphorylation of these sites is almost completely inhibited by rapamycin, mTORC1-activated $p70^{S6K1}$ is considered the predominant kinase responsible for rpS6 phosphorylation (Blenis et al. 1991; Chung et al. 1992). Thus, rpS6 phosphorylation (S235/236 and S240/244) is frequently used as a marker of changes in mTORC1 signaling. Recent studies have demonstrated, however, that relatively smaller contributions to rpS6 S235/236 phosphorylation are also made by Ras/ERK/RSK and cAMP-dependent kinase signaling pathways (Pende et al. 2004; Roux et al. 2007; Moore et al. 2009). The exact role that rpS6 plays in the regulation of protein synthesis and cell size remains unclear. Initially, because rpS6 was shown to interact with mRNA and translation initiation and elongation factors (Nygard and Nilsson 1990) and was located at the interface between the 40S and 60S ribosomal subunits, it was thought that rpS6 played a positive role in the regulation of protein synthesis (Uchiyama et al. 1986). Other data, however, showed that rpS6 phosphorylation was not sufficient to stimulate protein synthesis (Kruppa and Clemens 1984; Tas and Martini 1987; Montine and Henshaw 1990). Moreover, cells from a knock-in mouse model that expresses an rpS6 mutant that cannot be phosphorylated display an increase in protein synthesis (Ruvinsky et al. 2005), suggesting that phosphorylated rpS6 may in fact play an inhibitory role in the regulation of translation initiation and protein synthesis. Phosphorylated $p70^{S6K1}$ and rpS6 were also thought to play a role in the translation of a group of mRNAs, known as 5'-tract of pyrimidine (5'-TOP) mRNAs, that encode for translation factors and ribosomal proteins (Jefferies et al. 1994, 1997); however, this was not supported by later evidence (Pende et al. 2004; Ruvinsky et al. 2005). Thus, while rpS6 phosphorylation is

commonly used as an indirect marker of mTORC1 activation, the exact role that rpS6 plays in the regulation of protein synthesis and cell size remains to be determined.

Finally, mTORC1 and $p70^{S6K1}$ not only play a role in the acute regulation of translation initiation but may also play a role in the regulation of the number of ribosomes (i.e., ribosome biogenesis) and, thus, translational capacity (Mayer and Grummt 2006; Jastrzebski et al. 2007). Indeed, $p70^{S6K1}$ has been shown to be necessary and sufficient to increase ribosomal DNA transcription via the phosphorylation of the rDNA transcription factor, UBF (upstream binding factor) (Hannan et al. 2003). Furthermore, recent data shows that $p70^{S6K1}$ regulates the expression of a large proportion of genes involved in the ribosome biogenesis transcriptional program (Chauvin et al. 2013). Lastly, mTORC1-mediated signaling through $p70^{S6K1}$ is also required for growth signaling-induced increases in the de novo synthesis of pyrimidine nucleotides (i.e., cytosine, thymine, and uracil) (Ben-Sahra et al. 2013). This mechanism would appear to nicely link mTORC1-mediated DNA and RNA synthesis with an increase in the pool of the nucleotides required for these processes.

In summary, $p70^{S6K1}$ T389 phosphorylation is one of the most widely used markers of mTORC1 signaling. While the functional role of $p70^{S6K1}$ -induced phosphorylation of rpS6 remains to be determined, $p70^{S6K1}$ activation by mTORC1 has the potential to play a significant role in the acute, and longer-term, regulation of protein synthesis by phosphorylating substrates involved in translation initiation and elongation (i.e., eIF4B, eEF2 kinase, and PDCD4) and by regulating the synthesis of rRNA and various transcription factors involved in ribosome biogenesis (Fig. 1). Despite these reported roles in the regulation of protein synthesis, it still remains to be determined whether mTORC1-mediated $p70^{S6K1}$ phosphorylation or $p70^{S6K1}$ -mediated phosphorylation of rpS6, eIF4B, eEF2 kinase, or PDCD4 is necessary for mechanically induced increases in protein synthesis and skeletal muscle mass.

2.3.3 The Eukaryotic Initiation Factor 4E-Binding Protein 1 (4E-BP1)

In 1980, a hyper-phosphorylated protein, with an apparent mass of 22 kDa (later determined to be ~12.5 kDa), was isolated from insulin-treated rat adipose cells and shown to remain soluble after boiling and acid treatment (Belsham and Denton 1980). Because of these unusual properties, this protein was given the name PHAS-I (phosphorylated heat- and acid-stable protein regulated by insulin) (Hu et al. 1994). Later, the rat PHAS-I protein was found to be homologous with a human protein that bound to eIF4E, named 4E-BP1 (eIF4E-binding protein 1) (Pause et al. 1994) [Note: Two other 4E-BP isoforms, 4E-BP2 and 3, have also been discovered in mammals with similar functions to 4E-BP1 (Pause et al. 1994; Poulin et al. 1998)].

4E-BP1 has since been shown to play a crucial role in the regulation of cap-dependent translation initiation and, thus, protein synthesis. Specifically,

hypo-phosphorylated 4E-BP1 binds to eIF4E (which binds to the 7-methylguanosine "cap" structure found on the 5'-end of all nuclear-encoded mRNAs) and, in turn, inhibits cap-bound eIF4E from interacting with the scaffold protein eIF4G, the subsequent formation of the eIF4F complex, and the recruitment of the 40S ribosomal subunit (Mahoney et al. 2009). Thus, hypo-phosphorylated 4E-BP1 effectively suppresses the initiation of cap-dependent translation. Importantly, insulin and growth factors were shown to induce 4E-BP1 phosphorylation, which inhibited its ability to bind to eIF4E and relieved its repression of cap-dependent translation initiation. Furthermore, this insulin/growth factor-induced phosphorylation of 4E-BP1 was found to be inhibited by rapamycin (Graves et al. 1995; Azpiazu et al. 1996; von Manteuffel et al. 1996, 1997; Brunn et al. 1997b; Burnett et al. 1998). Significantly, this provided the first evidence that mTORC1 was responsible for the hyper-phosphorylation of 4E-BP1 and the associated increase in translation initiation.

4E-BP1 has numerous phosphorylation sites, and of these, T36, T45, S64, and T69 in rodent cells and T37, T46, S65, and T70 in humans are the most responsive to insulin stimulation (Fadden et al. 1997). While the phosphorylation of all these sites has been shown to be inhibited by rapamycin, albeit with differing sensitivities, mTORC1 has been reported to preferentially phosphorylate the T36 and T45 residues (Brunn et al. 1997a; Burnett et al. 1998; Gingras et al. 1999; Yang et al. 1999). Thus, 4E-BP1 is a major target of mTORC1 signaling and plays a significant role in the regulation of translation initiation and protein synthesis. While mechanically induced increases in 4E-BP1 phosphorylation are currently used as a marker of the activation of mTORC1 signaling in skeletal muscle, relatively little is known about the necessity of mTORC1-mediated phosphorylation of 4E-BP1 for increases in translation initiation, protein synthesis, and skeletal muscle mass in response to different types of mechanical activation.

2.3.4 Role of 4E-BP1 in Inhibiting the Translation of "Weak" and 5'TOP mRNAs

mTORC1-mediated phosphorylation of 4E-BP1 is proposed to not only play a role in the acute upregulation of translation initiation, and thus global rates of protein synthesis, but also in the selective translation of two groups of mRNAs that are crucial for cell growth and proliferation. The first of these groups is mRNAs that contain relatively long, highly structured, guanine/cytosine (GC)-rich 5'-untranslated regions (5'-UTR). It is proposed that because of the presence of the complex 5'-UTR structure, these mRNAs are translated with much less efficiency under basal conditions than mRNAs with relatively short and uncomplicated 5'-UTR structures, such as those found for "housekeeping" mRNAs [for a review, see (De Benedetti and Graff 2004)]. Indeed, by virtue of the fact that they are translated with less efficiency, mRNAs with highly structured 5'-UTRs are sometimes called "weak" mRNAs, while those with simple 5'-UTRs, which are translated more efficiently, are called "strong" mRNAs.

Importantly, "weak" mRNAs are reported to be particularly sensitive to changes in the availability of eIF4E (De Benedetti and Graff 2004). Thus, mTORC1-mediated phosphorylation of 4E-BP1, and its subsequent dissociation from eIF4E, effectively increases eIF4E availability and may induce an increase in the translation of these "weak" mRNAs that facilitate cell growth. Relevant examples of "weak" mRNAs that are known to play a significant role in cell growth are cyclin D1, c-Myc, and ornithine decarboxylase. Thus, mechanical stimuli may, in part, regulate skeletal muscle mass by increasing mTORC1/eIF4E-mediated translation of "weak" growth-related mRNAs. Interestingly, cyclin D1, c-Myc, and ornithine decarboxylase have previously been proposed to play a role in mechanically induced skeletal muscle hypertrophy (Alway 1997; Armstrong and Esser 2005; White et al. 2009; Lee and MacLean 2011).

The second group of mRNAs that are regulated by the mTORC1-mediated phosphorylation of 4E-BP1 are those that contain a tract of pyrimidines (TOP) in their 5'-UTR, known as 5'-TOP mRNAs (Huo et al. 2012; Thoreen et al. 2012). 5'-TOP mRNAs are characterized as containing a cytidine nucleoside immediately downstream of the 7-methylguanosine cap structure, which is followed by a sequence, or tract, of 4–15 pyrimidine nucleotides (cytosine or uracil). Importantly, 5'-TOP mRNAs typically encode for translation initiation and elongation factors and ribosomal proteins (Meyuhas and Dreaen 2009; Thoreen et al. 2012). Thus, an increase in the translation of 5'-TOP mRNAs has the potential to increase protein synthesis by increasing both translation initiation and ribosome biogenesis. The translation of 5'-TOP mRNAs is increased by serum, amino acid, and growth factor stimulation and is partially inhibited by rapamycin (Jefferies et al. 1994; Tang et al. 2001; Stolovich et al. 2002). Initially, an increase in the translation of 5'-TOP mRNAs was thought to be correlated with increased p70^{S6K1} and rpS6 phosphorylation (Jefferies et al. 1994, 1997); however, rapamycin-sensitive 5'-TOP mRNA translation was later found to be normal in p70^{S6K1} & 2-deficient and rpS6 phosphorylation-deficient cells (Pende et al. 2004; Ruvinsky et al. 2005). More recently, however, 5'-TOP mRNA translation has been found to be highly sensitive to changes in mTORC1-mediated 4E-BP1 phosphorylation. For example, it has recently been shown that while the ATP-competitive mTOR inhibitor Torin1 markedly inhibited protein synthesis in wild-type cells, it had a very minimal effect on protein synthesis in cells deficient in both 4E-BP1 and 2 (Thoreen et al. 2012). Moreover, Torin1 also reduced 5'-TOP mRNA translation in wild-type, but not 4E-BP1/2-deficient, cells (Thoreen et al. 2012). This data indicates that, at least in non-muscle cells, mTORC1-mediated phosphorylation of 4E-BPs plays a major role in the regulation of 5'-TOP mRNA translation and global protein synthesis. However, the importance of mTORC1-mediated 5'-TOP mRNA translation for mechanically induced increases in protein synthesis and skeletal muscle mass still remains to be determined.

In summary, mTORC1-mediated 4E-BP1 phosphorylation has the potential to increase global rates of protein synthesis not only by an acute increase in

eIF4E-mediated cap-dependent translation initiation but also by a selective increase in the translation of growth-related "weak" and 5'-TOP mRNAs that are vitally important for facilitating cell growth (Fig. 1). Significantly more research is required to determine the necessity of these events for increases in protein synthesis and muscle mass in response to mechanical stimuli.

2.3.5 The Eukaryotic Initiation Factor 2B Subunit ϵ (eIF2Be)

The eIF2Be is a subunit of the eIF2B holoenzyme which, in turn, makes up part of the larger eIF2 complex. The eIF2 complex plays a key role in the process of translation initiation. Specifically, in a GTP-dependent manner, eIF2 delivers the initiator tRNA (Met-tRNA_i) to the ribosome during the formation of the 48S preinitiation complex [for reviews, see (Kimball 1999; Proud 2005)]. The GTP on eIF2 is subsequently hydrolyzed to GDP, causing the release of GDP-bound eIF2 and other initiation factors from the 48S preinitiation complex, which ultimately allows the formation of the functional 80S ribosome and the commencement of translation elongation (Kimball 1999; Proud 2005). In order to participate in another round of translation initiation, the GDP bound to eIF2 is exchanged for GTP, a reaction that is catalyzed by the eIF2B holoenzyme (Kimball 1999; Proud 2005). Importantly, the eIF2Be subunit serves the catalytic function of eIF2B and its activity can be regulated by a variety of stimuli, including hormones, nutrients, and mechanical loading (Gilligan et al. 1996; Welsh et al. 1996; Kimball et al. 1998; Kostyak et al. 2001; Bush et al. 2003).

Recent studies have shown that the overexpression of eIF2Be is sufficient to induce an increase in eIF2B activity and protein synthesis, while knockdown of eIF2Be results in a decrease in protein synthesis (Gallagher et al. 2008; Kubica et al. 2008). Together, these observations suggest that the abundance of eIF2Be may be a rate-limiting factor for protein synthesis. Several studies have also shown that, in skeletal muscle, the activity of eIF2B correlates well with the changes in protein synthesis that occur in response to various conditions including increased mechanical loading (Kimball et al. 1998; Kostyak et al. 2001; Tuckow et al. 2010). Moreover, previous studies have shown that eIF2Be abundance is elevated by increased mechanical loading (Kostyak et al. 2001; Kubica et al. 2004, 2005; Fluckey et al. 2006; Mayhew et al. 2011) and that overexpression of eIF2Be is sufficient to induce muscle fiber hypertrophy in vivo (Mayhew et al. 2011). Importantly, recent reports also show that rapamycin is sufficient to inhibit leucine-, IGF-1-, and resistance exercise-induced increases in the abundance of eIF2Be, indicating that mTORC1 signaling is necessary to increase eIF2Be abundance (Kubica et al. 2005, 2008); however, the mechanism via which mTORC1 regulates eIF2Be remains to be determined. Nevertheless, mTORC1-mediated increases in the abundance of eIF2Be and a subsequent increase in eIF2B activity may play a significant role in regulating mechanical load-induced increases in protein synthesis and muscle mass.

2.4 New-Generation ATP-Competitive mTOR Inhibitors and Their Implications for Understanding mTORC1-Mediated Processes

As indicated above, rapamycin forms a complex with FKBP12, which then binds to the FRB domain of mTOR and acts as an allosteric inhibitor of mTOR kinase activity. The mechanism behind rapamycin's inhibitory effect has been suggested to involve the dissociation of Raptor from mTOR leading to reduced mTOR interaction with its Raptor-bound substrates (Oshiro et al. 2004), competition between the inhibitory rapamycin/FKBP12 complex and the mTOR activator phosphatidic acid (PA) for binding to the mTOR FRB domain (Fang et al. 2001), and/or reduced mTOR-mediated repression of protein phosphatase activity (Peterson et al. 1999). A recent crystallography study has shed further light on this issue, demonstrating that rapamycin/FKBP12 complex binding to the FRB domain effectively blocks the binding of mTOR substrates to mTOR and restricts their access to the active catalytic site (Yang et al. 2013).

While rapamycin has played a pivotal role in the discovery of various mTORC1 substrates, the difference in the efficacy of rapamycin to inhibit protein synthesis and cell cycle progression in yeast compared to mammalian cells prompted the suggestion that some mTORC1-mediated events may be resistant to the inhibitory effects of rapamycin in mammalian cells (Thoreen and Sabatini 2009). This observation, in part, led to the development of a new class of small-molecule mTOR inhibitors that function by directly competing with ATP binding to mTOR (e.g., PP242, Torin1, and WYE-354) and, thus, directly inhibiting mTOR kinase activity (Feldman et al. 2009; Thoreen et al. 2009; Yu et al. 2009). Although these drugs inhibit mTOR in both mTORC1 and mTORC2, using cells that lack Rictor and, thus, mTORC2, Thoreen et al. (2009) showed that Torin1 inhibited protein synthesis to a greater extent than rapamycin and confirmed the presence of rapamycin-resistant, but mTORC1-dependent, events within mammalian cells (Thoreen et al. 2009). This finding is potentially very important because events that have previously been reported to be partially rapamycin sensitive, or even mTORC1 independent, may in fact be mediated by mTORC1.

Another important implication of these new findings is that caution should be used when using a marker of mTORC1 signaling (e.g., p70^{S6K1} T389 phosphorylation) as the only readout to indicate that rapamycin has fully inhibited mTORC1 signaling. This caution is warranted because studies have shown that rapamycin has differential effects on the phosphorylation of p70^{S6K1} compared to 4E-BP1, such that p70^{S6K1} T389 phosphorylation is strongly inhibited by rapamycin whereas 4E-BP1 T37/46 phosphorylation is largely resistant to rapamycin-induced inhibition [e.g., (Choo et al. 2008; Thoreen et al. 2009)]. Indeed, Kang et al. (2013) recently characterized the p70^{S6K1} T389 and 4E-BP1 S64 residues as "poor" mTORC1 substrates and, thus, easily inhibited by rapamycin. Conversely, the 4E-BP1 T37/46 residues were characterized as "good" mTORC1 substrates and, thus, markedly less sensitive to rapamycin inhibition (Kang et al. 2013).

The implication of this new data is that although rapamycin may fully inhibit p70^{S6K1} T389 phosphorylation, depending on the dose and duration of exposure, this does not necessarily mean that mTORC1 activity toward "good" targets like 4E-BP1 T37/46 has been fully inhibited. While the use of the ATP-competitive inhibitors may seem like a potential solution to the limitations of rapamycin, these could prove to be just as problematic as they inhibit both mTORC1 and mTORC2 signaling which could introduce a range of confounding effects that severely limit data interpretation. Overall, the findings obtained with the new ATP-competitive mTOR inhibitors show that rapamycin does not completely inhibit all of mTORC1's signaling events and suggest that mTORC1 may have more downstream, rapamycin-insensitive, targets than previously recognized. Moreover, the relative role(s) of "poor" versus "good" mTORC1 substrates in mechanically induced increases in protein synthesis and skeletal muscle mass remain to be determined.

3 The Role of mTORC1 in the Regulation of Mechanical Stimuli-Induced and Basal Rates of Protein Synthesis

It is well known that mTORC1 signaling regulates protein synthesis and cell size in a variety of cell types, including muscle cells, in response to mitogens such as insulin or IGF-1 [e.g., (Dardevet et al. 1996; Rommel et al. 2001; Glass 2010; Schiaffino and Mammucari 2011)]. Over the last ~15 years, a significant body of evidence has also developed describing the role that mTORC1 plays in the regulation of skeletal muscle mass and protein synthesis in response to different types of mechanical activation. In this section, we will review the evidence, from rodent and human studies, for whether mTORC1 is activated by overload/resistance, endurance, and sprint types of exercise. Furthermore, we will examine whether there is evidence showing that mTORC1 signaling is necessary for changes in protein synthesis and muscle mass in response to these types of exercise. Finally, the role of mTORC1 signaling in basal protein synthesis and muscle mass will also be explored.

3.1 Evidence for the Role of mTORC1 in the Regulation of Muscle Mass and Protein Synthesis in Response to Increased Mechanical Loading or Resistance Exercise

Resistance exercise is the most commonly used model of mechanical overload for increasing strength and skeletal muscle mass. Using this model, numerous human studies have shown that acute resistance exercise induces an increase in muscle protein synthesis rates for up to 48 h post exercise [e.g., (Chesley et al. 1992; MacDougall et al. 1995; Phillips et al. 1997; Welle et al. 1999; Trappe et al. 2002; Dreyer et al. 2008)] and that prolonged resistance training results in significant

whole muscle and muscle fiber hypertrophy [e.g., (Cureton et al. 1988; Staron et al. 1990; McCall et al. 1996; Kraemer et al. 2004; Leger et al. 2006; Thalacker-Mercer et al. 2013)]. Given mTORC1's proposed roles in the regulation of translation and cell growth, we will next examine evidence from human and rodent studies for whether mTORC1 signaling plays a role in inducing an increase in protein synthesis and muscle mass in response to resistance-type exercise.

3.1.1 Rodent Studies

Baar and Esser (1999) performed the first study to examine whether the increase in muscle mass that occurs in response to high-resistance exercise training was associated with an increase in mTORC1 signaling (Baar and Esser 1999). This study showed that the increase in the mass of rat muscles subjected to 6 weeks of high-intensity eccentric contraction training was highly correlated with the magnitude of the increase in p70^{S6K1} phosphorylation at 6 h after the first exercise bout. Furthermore, they found that eccentric contractions induced an increase in the size of the polysome pool, an indicator of increased translation initiation. Thus, this study provided the first evidence that increased mechanical loading was associated with increased mTORC1 signaling, protein synthesis, and muscle hypertrophy. Since this seminal study, numerous rodent studies have reported increased mTORC1 signaling in response to various forms of acute and chronic mechanical overload models, including stretched cultured myoblasts and myotubes (Hornberger et al. 2005a; Frey et al. 2009; Nakai et al. 2010; Sasai et al. 2010), ex vivo passive stretch of isolated muscles (Hornberger et al. 2004, 2005b, 2006; Hornberger and Chien 2006; You et al. 2012), in vivo maximal isometric contractions (Ogasawara et al. 2013), in vivo high-resistance eccentric and concentric contractions (Parkington et al. 2003; Burry et al. 2007; Thomson et al. 2008; O'Neil et al. 2009; Witkowski et al. 2010), and chronic mechanical overload induced by synergist ablation (SA) surgery (Hornberger et al. 2003; Thomson and Gordon 2006; Spangenburg et al. 2008; Thomson et al. 2009; Goodman et al. 2011a; Miyazaki et al. 2011). However, the first evidence that mTORC1 signaling was not only associated with, but also necessary for, mechanical load-induced growth came from the study of Bodine et al. (2001). In this study, rapamycin was shown to inhibit SA-induced muscle hypertrophy, and this was associated with an inhibition of p70^{S6K1} phosphorylation, an increase in 4E-BP1/eIF4E binding, and a decrease in eIF4E/eIF4G interaction (Bodine et al. 2001).

One issue that remained after the study of Bodine et al. (2001) was that, because systemic administration of rapamycin would be expected to inhibit mTORC1 signaling in all cells throughout the body, it was not clear if the anti-hypertrophic effects of rapamycin were due to the inhibition of mTORC1 signaling in skeletal muscle cells per se, or other cell types within skeletal muscle tissue (e.g., immune cells), or distant effects in other tissues. This was an important point because several studies had shown that immune cells may play an important role in mechanically induced skeletal muscle hypertrophy (DiPasquale et al. 2007; Marino et al. 2008; Novak et al. 2009; Dearth et al. 2013), and rapamycin potentially could inhibit their

ability to proliferate and function normally. Thus, using mice with skeletal muscle cell-specific expression of rapamycin-resistant (RR) or rapamycin-resistant kinase dead (RRKD) mutants of mTOR, Goodman et al. (2011a) investigated this issue and demonstrated that, like Bodine et al. (2001), rapamycin inhibited SA-induced increase in p70^{S6K1} T389 phosphorylation and muscle fiber hypertrophy in wild-type mice (Goodman et al. 2011a). Importantly, however, both of these effects of rapamycin were rescued in RR mice but not in RRKD mice. These results clearly demonstrated that mTOR/mTORC1 kinase activity, specifically in skeletal muscle cells, and not in other cell types (e.g., immune cells), was required for the SA-induced hypertrophic response (Goodman et al. 2011a). More recently, 7 and 28 days of SA-induced chronic mechanical overload failed to induce muscle fiber hypertrophy in mice lacking Raptor expression, and thus mTORC1, specifically in skeletal muscle (Bentzinger et al. 2013). Combined, these studies show that increased mechanical loading is sufficient to activate skeletal muscle mTORC1 signaling and that skeletal muscle cell-specific mTORC1 kinase activity is necessary for muscle fiber hypertrophy induced by increased mechanical loading.

It has long been known that increased mechanical loading of rodent skeletal muscle results in an increase in protein synthesis and that this is, in part, responsible for load-induced muscle hypertrophy (Goldberg et al. 1975; Booth et al. 1982). This suggests that mTORC1 signaling may play a role in the acute mechanical load-induced increases in protein synthesis. Indeed, the activation of mTORC1 signaling by the GTPase Rheb, one of the most proximal activators of mTOR, has been shown to be sufficient to increase muscle fiber protein synthesis and cross-sectional area in vivo (Goodman et al. 2010, 2011b), providing further support for the idea that mechanical activation of mTORC1 may play an important role in the regulation of protein synthesis. More direct evidence to support this idea comes from Hornberger et al. (2004) who showed that the increase in mTORC1 signaling and protein synthesis, induced by ex vivo passive stretch of mouse EDL muscles, was completely inhibited in the presence of rapamycin (Hornberger et al. 2004). Similarly, Kubica et al. (2005) demonstrated that rapamycin inhibited the in vivo resistance exercise-induced increase in mTORC1 signaling, translation initiation, and protein synthesis at 16 h post exercise in rat skeletal muscle (Kubica et al. 2005). Combined, these few studies show that mTORC1 signaling is necessary for the increase in protein synthesis in rodent skeletal muscle, in response to increased mechanical loading.

In summary, studies in rodents clearly show that (1) increased mechanical loading is sufficient to activate mTORC1 signaling, (2) activation of mTORC1 is sufficient to induce an increase in protein synthesis and muscle fiber hypertrophy, and (3) mTORC1 kinase activity is necessary for mechanical load-induced increases in protein synthesis and muscle hypertrophy.

3.1.2 Human Studies

As mentioned above, many studies have shown that resistance exercise is sufficient to induce an increase in protein synthesis and stimulate skeletal muscle

hypertrophy. Moreover, many studies have also shown that acute heavy resistance exercise is sufficient to induce a significant increase in markers of mTORC1 signaling (typically, p70^{S6K1} or 4E-BP1 phosphorylation) [e.g., (Deldicque et al. 2005; Cuthbertson et al. 2006; Dreyer et al. 2006; Eliasson et al. 2006; Glover et al. 2008; Witard et al. 2009; Holm et al. 2010)]. Indeed, similar to the rodent study of Baar and Esser (1999), Terzis et al. (2008) showed in humans that the increase in p70^{S6K1} T389 phosphorylation, 30 min after the first resistance training bout, was highly correlated with measures of whole muscle and muscle fiber hypertrophy induced by 14 weeks of high-intensity resistance training (Terzis et al. 2008). These data show that mTORC1 signaling is activated by resistance exercise in human skeletal muscle and, similar to rodent studies, suggests that mTORC1 signaling may also play a major role in mediating resistance exercise-induced increases in skeletal muscle mass in humans. To date, however, there are currently no studies that have used rapamycin to investigate whether mTORC1 signaling is necessary for resistance training-induced muscle hypertrophy. While more studies are needed to clarify this question, there may be significant issues in the approval of studies that aim to administer rapamycin, or another mTOR/mTORC1 inhibitor, for a prolonged period of time to human subjects.

In regard to protein synthesis, to date, only one human study has used rapamycin to determine whether mTORC1 signaling regulates skeletal muscle protein synthesis in response to an acute bout of resistance exercise. This study by Drummond et al. (2009) found that rapamycin completely inhibited the early (1–2 h) resistance exercise-induced increase in protein synthesis (Drummond et al. 2009). Unlike the rodent studies, however, rapamycin only delayed or partially inhibited markers of mTORC1 signaling over this time period. Indeed, rapamycin inhibited the resistance exercise-induced increase in p70^{S6K1} T389 phosphorylation 1 h, but not 2 h, post exercise, and had no effect on 4E-BP1 T37/46 phosphorylation. The reason for the apparent discrepancy between this study and the in vivo rat study of Kubica et al. (2005) in the ability of rapamycin to inhibit markers of mTORC1 signaling could be related to the dose of rapamycin (~0.15 mg/kg vs. 0.75 mg/kg, respectively) and time point after exercise (1–2 h vs. 16 h, respectively). The study of Drummond et al. may also suggest that a complete inhibition of mTORC1 signaling may not be required to fully inhibit the resistance exercise-induced increase in protein synthesis. Indeed, perhaps acute mechanically induced increases in protein synthesis are "predominantly driven by mTORC1 signaling targets that are highly sensitive to rapamycin, such as p70^{S6K1} T389 phosphorylation, and not by the more rapamycin-resistant mTORC1 substrates, such as 4E-BP1 T37/46 phosphorylation. Alternatively, the post-resistance-exercise-induced increase in protein synthesis in humans may be mediated, in part, by a rapamycin-sensitive mTOR that is not part of the traditional mTORC1. Further studies are therefore required to better determine the requirement of mTORC1 signaling for resistance exercise-induced increases in protein synthesis and muscle mass in humans.

In summary, heavy resistance exercise in humans is sufficient to increase post-exercise markers of mTORC1 signaling, protein synthesis, and induce skeletal

muscle hypertrophy. To date, one study has reported that the acute resistance exercise-induced increase in muscle protein synthesis is inhibited by a relatively low dose of rapamycin, suggesting that mTORC1 signaling is necessary for this event. Furthermore, no human studies have investigated the necessity of mTORC1 for resistance training-induced skeletal muscle hypertrophy. Clearly, more studies are required to establish the role of mTORC1 signaling in response to resistance exercise in humans.

3.2 Evidence for the Role of mTORC1 Signaling in the Regulation of Protein Synthesis in Recovery from Acute Endurance Exercise

In contrast to resistance exercise, endurance exercise is characterized by the repetition of low to moderate force contractions over a prolonged period of time. While there is significant evidence that protein synthesis is depressed during acute endurance exercise [for a review, see (Rose and Richter 2009)], several studies have shown an increase in muscle protein synthesis for many hours after endurance exercise [e.g., (Carraro et al. 1990; Sheffield-Moore et al. 2004; Miller et al. 2005; Harber et al. 2009a; Mascher et al. 2011)]. This increase in protein synthesis during recovery from endurance exercise may be due to the increased synthesis of mitochondrial proteins and/or the turnover of proteins damaged during the exercise bout [e.g., calcium-activated protease- or oxidative stress-induced damage (Overgaard et al. 2004; Seene et al. 2011)]. Moreover, endurance training has also been shown to increase resting muscle protein synthesis (Short et al. 2004; Pikosky et al. 2006) and induce whole muscle and muscle fiber hypertrophy in relatively sedentary subjects [e.g., (Verney et al. 2008; Harber et al. 2009b; Hudelmaier et al. 2010; Konopka et al. 2010; Lovell et al. 2010; McPhee et al. 2010)], albeit to a lesser extent than that induced by resistance training. Given the role of mTORC1 in the regulation of resistance exercise-induced increases in protein synthesis, could there also be a role for mTORC1 in mediating post-endurance-exercise increases in protein synthesis? Unfortunately, to date, there are no studies that have performed acute endurance exercise in combination with rapamycin administration to determine whether mTORC1 plays a necessary role in endurance exercise-induced increases in post-exercise protein synthesis. Nevertheless, some progress has been made in relation to the effect of endurance exercise on mTORC1 signaling and/or protein synthesis in rodents and humans.

3.2.1 Rodent Studies

To date, only a few studies have examined the effect of prolonged repeated contractions or endurance-type exercise on post-exercise mTORC1 signaling and/or protein

synthesis in rodent skeletal muscle. Some of the first studies showed that skeletal muscle protein synthesis rates were depressed 1 h after a 2 h bout of treadmill running in rats that were fasted or fed a carbohydrate meal immediately post exercise (Gautsch et al. 1998; Anthony et al. 2007). This depressed protein synthesis was associated with either no change or a decrease in p70^{S6K1} phosphorylation, a reduction in 4E-BP1 phosphorylation, a reduction in the eIF4E/eIF4G binding, and an increase in eIF4E/4E-BP1 binding (Gautsch et al. 1998; Anthony et al. 2007). Later, using prolonged (3 h) ex vivo low frequency (10 Hz) stimulation of rat skeletal muscle, Atherton et al. (2005) found a trend for increases in myofibrillar and sarcoplasmic protein synthesis 3 h post exercise. Interestingly, this was associated with reduced p70^{S6K1} T389 and 4E-BP1 T37/46 phosphorylation, indicating an inhibition of mTORC1 signaling (Atherton et al. 2005). While this study suggests a dissociation between post-stimulation protein synthesis and mTORC1 signaling, the reduced mTORC1 signaling may, in part, be due to the absence of amino acids in the incubating medium (Atherton et al. 2005). More recently, Edgett et al. (2013) reported that over 2 h of exhaustive treadmill running in rats induced an increase in p70^{S6K1} T389, but not 4E-BP1 T37/46, phosphorylation immediately post exercise, an effect that had largely receded by 3 h post exercise (Edgett et al. 2013). Finally, Ito et al. (2013a) recently reported a significant increase in p70^{S6K1} T389 phosphorylation immediately after 30 min of forced incremental-speed treadmill running in mice (Ito et al. 2013a). Overall, these few studies highlight that there is currently no clear picture for the effect of acute endurance exercise on post-exercise mTORC1 signaling and protein synthesis in rodents. The differences in results between these studies may be due to differences in species, contraction/exercise protocols, nutritional status, and/or sample timing. Clearly, more studies are required to obtain a more definitive answer to the question of whether mTORC1 plays any role in the acute response, and more chronic adaptation, to endurance exercise in rodents.

3.2.2 Human Studies

Several human studies have reported that acute endurance exercise (one- or two-legged cycling) is sufficient to increase mTORC1 signaling at various early time points after exercise (0.5–3 h) in relatively well-trained subjects [e.g., (Coffey et al. 2006; Mascher et al. 2007; Benziene et al. 2008; Camera et al. 2010; Wang et al. 2011)]. Furthermore, a few human studies have examined changes in both protein synthesis and markers of mTORC1 signaling after acute endurance exercise. Of these, Wilkinson et al. (2008) found that p70^{S6K1} T389 phosphorylation was elevated approximately twofold immediately after 45 min of one-legged cycling (75 % VO_{2peak}) in fed trained and untrained subjects. Moreover, this increase in mTORC1 signaling was associated with an increase in mitochondrial, but not myofibrillar, protein synthesis, over the first 4 h post exercise (Wilkinson et al. 2008). Also, Mascher et al. (2011) reported an increase in mixed muscle protein synthesis at 3 h after a 60 min bout of one-legged cycling (65–70 % VO_{2max}) in fasted trained subjects which was associated with increased p70^{S6K1}

T389 phosphorylation at 90 min and 3 h post exercise (Mascher et al. 2011). Furthermore, Beelen et al. (2011) reported an increase in mixed muscle protein synthesis during 2 h of cycling (55 % W_{\max}) in fed trained subjects which corresponded with increased $p70^{S6K1}$ T389, but not 4E-BP1 T37, phosphorylation (Beelen et al. 2011). Finally, it was recently shown that 1 h of cycling (72 % VO_{2peak}) was sufficient to increase mixed muscle protein synthesis (~60 %) at 2 h post exercise in active, but untrained, subjects (Harber et al. 2010; Reidy et al. 2013). Interestingly, at this time point there was no significant exercise-induced increase in $p70^{S6K1}$ T389 or 4E-BP1 T37/46 phosphorylation (Harber et al. 2010; Reidy et al. 2013). While these results suggest that mTORC1 signaling was not activated by the endurance exercise, mTORC1 signaling may have been elevated at an earlier time and subsequently subsided.

Overall, unlike the rodent studies, many human studies show that acute endurance cycling exercise is sufficient to induce an increase in post-exercise mTORC1 signaling, while a limited number of studies have found an associated increase in post-exercise muscle protein synthesis. This increase in muscle protein synthesis may, in part, be due to an increase in the synthesis of new mitochondrial proteins and/or the replacement of proteins damaged by reactive oxygen species or Ca^{2+} -activated proteases. Whether mTORC1 signaling is required for the increase in protein synthesis and for endurance training-induced muscle fiber hypertrophy still remains to be determined. Lastly, there are currently no human studies that have examined the effect of prolonged running or swimming exercise on post-exercise mTORC1 signaling or protein synthesis. Thus, significantly more research is required to obtain a better understanding of the role of mTORC1 signaling in mediating the acute responses and chronic adaptations to endurance exercise.

3.3 Evidence for the Activation of mTORC1 Signaling by High-Intensity Sprint Exercise

Sprint exercise is characterized by high-velocity, high-power-output contractions over relatively short periods of time. Some, but not all, studies have reported that sprint training can induce increases in muscle fiber size [for a review, see (Ross and Leveritt 2001)]. Thus, sprint training-induced muscle fiber hypertrophy could, in part, be due to an mTORC1-mediated increase in protein synthesis. Unfortunately, however, to date no studies have examined whether single or repeated sprints are sufficient to increase muscle protein synthesis rates above basal levels. There are, however, a few recent studies that have examined changes in mTORC1 signaling in response to acute sprint exercise. For example, Gibala et al. (2009) reported no change in $p70^{S6K1}$ T389 or 4E-BP1 T37/46 phosphorylation in male subjects immediately after a single maximal 30 s cycling sprint, immediately after four 30 s sprints separated by 4 min rest periods, or 3 h after the fourth sprint (Gibala et al. 2009). Coffey et al. (2011) showed that ten 6 s cycling sprints in fasted male subjects (placebo group) tended to increase $p70^{S6K1}$ T389 phosphorylation

and induced a decrease in 4E-BP1 T37/46 phosphorylation 15 min post exercise, with both of these returning to basal levels by 4 h post exercise (Coffey et al. 2011). More recently, Esbjörnsson et al. (2012) reported a significant increase in $p70^{S6K1}$ T389 phosphorylation in fasted physically active men and women 2 h after performing three 30 s cycling sprints with 20 min rest periods between sprints (Esbjörnsson et al. 2012). Moreover, the increase in $p70^{S6K1}$ T389 phosphorylation was greatest in female subjects, suggesting sex-based differences in sprint exercise-induced mTORC1 signaling. Finally, Rundqvist et al. (2013) had physically active subjects (predominantly male) perform three 30 s maximal cycling sprints, each separated by a 20 min rest period, combined with either repeated ingestion of a nutritional supplement (essential amino acids and carbohydrate) or a placebo. The results showed that at 140 min post exercise, $p70^{S6K1}$ T389 phosphorylation remained unchanged in the placebo condition but increased ~15-fold with ingestion of the nutritional supplement (Rundqvist et al. 2013).

Overall, significant variation exists in the limited results from a few studies that have investigated the effect of acute sprint exercise on skeletal muscle mTORC1 signaling and protein synthesis. This variability is likely due, in part, to differences in the duration and number of sprint bouts, rest period duration, nutritional status, the timing of post-exercise sampling, and the sex, age, and training status of the subjects. Thus, more studies are required to investigate whether sprint exercise is sufficient to increase skeletal muscle protein synthesis and, if so, whether mTORC1 signaling is necessary for this to occur.

3.4 Does mTORC1 Signaling Regulate Basal Protein Synthesis and Resting Skeletal Muscle Mass?

With the exception of during sleep, even basic daily activities involve performing muscle contractions of varying number, intensity, and duration, and these contractions have the potential to play a role in the regulation of protein synthesis and muscle mass. Thus, it is also of interest to ask whether mTORC1 signaling plays a role in maintaining basal protein synthesis rates and/or muscle mass.

3.4.1 Protein Synthesis

Insights into the question of whether mTORC1 signaling is necessary for the regulation of basal protein synthesis rates in skeletal muscle come from a limited number of rodent and human studies that have used the mTORC1 inhibitor, rapamycin. For example, Hornberger et al. (2004) reported that 2 h *ex vivo* incubation of mouse EDL muscles with a dose of rapamycin that was sufficient to inhibit passive stretch-induced increases in mTORC1 signaling and protein synthesis did not significantly reduce basal protein synthesis despite completely inhibiting basal

p70^{S6K1} T389 phosphorylation (Hornberger et al. 2004). Furthermore, Kubica et al. (2005) showed that an in vivo injection of rapamycin, at a dose sufficient to inhibit resistance exercise-induced increases in mTORC1 signaling and protein synthesis, had no effect on basal protein synthesis despite significantly reducing basal p70^{S6K1} and 4E-BP1 phosphorylation (Kubica et al. 2005). Similar to these rodent studies, human studies from the Rasmussen laboratory found that oral doses of rapamycin (administered 2 h prior to basal sample collection) that were sufficient to inhibit resistance exercise-induced and essential amino acid-induced increases in mTORC1 signaling and protein synthesis had no effect on basal protein synthesis (Drummond et al. 2009; Dickinson et al. 2011, 2013). It is worth noting, however, that although the dose of rapamycin used in these human studies did not affect basal protein synthesis, it also did not fully inhibit mTORC1 signaling. In a recent longer-term study, Drake et al. (2013) reported that 12 weeks of a rapamycin-containing diet induced a small but significant decrease in skeletal muscle protein synthesis in mixed and cytoplasmic fractions, but not in a mitochondrial fraction of mouse skeletal muscles (Drake et al. 2013). Unfortunately, it was not reported whether this rapamycin-induced decrease in protein synthesis was associated with a reduction in skeletal muscle mass. Thus, while short-term rapamycin administration does not seem to affect skeletal muscle protein synthesis, longer-term administration may induce a small decrease in protein synthesis. While these studies suggest that mTORC1-independent mechanisms may play a more dominant role in regulating basal protein synthesis in skeletal muscle, it cannot be ruled out that the rapamycin used in these studies did not fully inhibit mTORC1 signaling.

3.4.2 Muscle Mass

In regard to whether mTORC1 signaling is required for the maintenance of resting skeletal muscle mass, no studies have specifically attempted to address this question. Nonetheless, recent studies have shown that relatively short-term (7–14 days) daily rapamycin injections (0.6–1.0 mg/kg), which are sufficient to inhibit Rheb- and SA-induced p70^{S6K1} T389 phosphorylation and muscle fiber hypertrophy, had no effect on resting muscle fiber size in control mice (Goodman et al. 2010, 2011a). Furthermore, longer-term studies (4–6 months) using diet-based rapamycin ingestion have reported no effect on the mass of various hind limb muscles of young and aged mice (Fok et al. 2013; Neff et al. 2013; Zhang et al. 2013). Thus, notwithstanding the question of the ability of rapamycin to completely inhibit mTORC1 signaling, these rapamycin studies suggest that basal skeletal muscle mass is not regulated by mTORC1.

Recently, Bentzinger et al. (2008) developed a muscle-specific Raptor knockout (KO) mouse and, thus, a model of inhibited muscle mTORC1 signaling that could give insights into whether mTORC1 signaling plays a role in regulating basal muscle mass. This study showed that the absence of Raptor, and thus mTORC1 signaling, throughout development and maturation (up to ~90–140 days) resulted in a significant reduction in whole muscle mass and muscle fiber size compared to controls

(Bentzinger et al. 2008). This was associated with severely reduced rpS6 S235/236 and 4E-BP1 T65 phosphorylation. These observations suggest that mTORC1 signaling may play a role in the full development or maintenance of basal muscle mass; however, the fact that muscle mass was only ~20–30 % lower in the Raptor KO mice compared to controls indicates that other mTORC1-independent factors play a larger role in determining the basal levels of skeletal muscle mass. It should also be noted that the interpretation of data from these Raptor KO mice is complicated by the fact that these mice have a severely reduced life span, such that they begin to die at ~110 days (all are dead at 190 days), while healthy control mice usually live for 2–3 years (Bentzinger et al. 2008). Thus, the observations from these Raptor KO mice may, in large part, reflect accelerated aging and, thus, the early development of sarcopenia. To help avoid the extra variables introduced by the ablation of Raptor during development and the issues of premature aging, future studies on the necessity of Raptor and mTORC1 signaling for maintaining basal muscle mass could be performed by using an inducible muscle-specific Raptor KO model in young adult mice.

Overall, a very limited amount of short- and medium-term studies in rodents and humans suggest that mTORC1 signaling may not be necessary for maintaining basal rates of protein synthesis and basal levels of skeletal muscle mass. It is possible, however, that these findings may be affected by the inability of rapamycin to fully inhibit mTORC1 signaling (Thoreen et al. 2009, 2012). While data from Raptor knockout mice suggest that mTORC1 signaling may play a small role in determining basal skeletal muscle mass, this model also suggests that mTORC1-independent mechanisms play a more dominant role in the regulation of basal skeletal muscle mass. Thus, more studies are required to fully clarify the role, if any, of mTORC1 signaling in the regulation of basal protein synthesis and skeletal muscle mass.

4 Potential Activators of mTORC1 Signaling Induced by Mechanical Overload or Resistance Exercise

Given that the current evidence that mTORC1 signaling is necessary for the increases in protein synthesis, and possibly muscle mass, that occur in response to mechanical overload/resistance exercise, this final section will briefly examine the evidence for some of the putative mechanisms (Figs. 2, 3, and 4) that have been proposed to play a role in the activation of mTORC1 signaling by this form of mechanical stimuli.

4.1 Insulin-Like Growth Factor 1 (IGF-1)

More than two decades after early studies had shown that humoral factors, such as growth hormone and insulin, were not required for mechanical overload-induced




Fig. 2 Proposed molecular mechanisms for the mechanical activation of mTORC1 by IGF-1/PI3K/Akt, ERK1/2, and PDL1/PA signaling pathways. Current evidence suggests that the mechanical overload/resistance exercise-induced activation of mTOR complex 1 (mTORC1) signaling in skeletal muscle occurs through insulin-like growth factor 1 (IGF-1)/phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) independent pathways. Evidence obtained from rodent models strongly suggests phosphatidic acid (PA), produced by the zeta isoform of diacylglycerol kinase (DGK ζ), plays a significant role in the mechanical activation of mTORC1 signaling. See text for further details. Dashed lines (— —) indicate multiple steps between signaling molecules. Question mark (?) indicates that it is currently unknown whether mechanical stimuli are sufficient to activate mTORC1 signaling via PA produced by lysophosphatidic acid acyltransferases (LPAATs)

skeletal muscle hypertrophy (Goldberg 1967, 1968b), it was discovered that IGF-1 expression was induced in animal skeletal muscle by increased mechanical loading [e.g., (DeVol et al. 1990; Yan et al. 1993; Czerwinski et al. 1994; Goldspink et al. 1995; Adams and Haddad 1996)]. Indeed, mechanical stimuli were shown to increase the expression of several isoforms of IGF-1 in animal and human skeletal muscle, including one splice variant known as the mechano-growth factor (MGF), which was proposed to act in an autocrine manner (Perrone et al. 1995; Yang et al. 1996; McKoy et al. 1999; Hameed et al. 2003). Importantly, IGF-1 was shown to be sufficient to increase muscle protein synthesis (Monier et al. 1983; Gulve and Dice 1989) and to induce skeletal muscle hypertrophy (Coleman et al. 1995; Barton-Davis et al. 1998; Musaro et al. 2001). Moreover, IGF-1 was shown to activate the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in muscle cells in a rapamycin-sensitive manner (Fig. 2), indicating that IGF-1 activated mTORC1 signaling (Dardevet et al. 1996; Frost and Lang 1999; Rommel et al. 2001; Latres et al. 2005; Park et al. 2005). Thus, it was proposed

that mechanically induced IGF-1 expression may stimulate an increase in protein synthesis and induce muscle hypertrophy, in part, by the activation of mTORC1 signaling [Note: IGF-1 may also induce skeletal muscle hypertrophy via the activation and differentiation of quiescent satellite cells and the incorporation of new myonuclei into existing muscle fibers (Adams 1998); however, this is a controversial topic with recent data casting doubts on the function of the MGF and on the role of satellite cells in mechanically induced muscle hypertrophy. For further information on this topic, the reader is referred to the following papers: Adams 1998; Hill et al. 2003; McCarthy and Esser 2007; O'Connor and Pavlath 2007; O'Connor et al. 2007; Matheny et al. 2010; McCarthy et al. 2011; Fornaro et al. 2013].

While this IGF-1-centric hypothesis for explaining mechanically induced increases in mTORC1 signaling, protein synthesis, and skeletal muscle mass seemed very attractive, serious doubts have since emerged to challenge its validity (Philp et al. 2011). For example, several rodent studies have shown that skeletal muscle mTORC1 signaling can be activated by mechanical stimuli in a manner that is independent of PI3K/Akt signaling (Parkington et al. 2003; Hornberger et al. 2004; Hornberger and Chien 2006; O'Neil et al. 2009). Furthermore, studies using a transgenic mouse model that expresses a dominant-negative IGF-1 receptor specifically in skeletal muscle (MKR) have shown that, in the absence of IGF-1 signaling, chronic mechanical overload-induced mTORC1 signaling and muscle hypertrophy were identical to that in wild-type mice (Spangenburg et al. 2008). In addition, acute eccentric contractions in these MKR mice were sufficient to activate mTORC1 signaling (Witkowski et al. 2010). Further doubt comes from studies showing that acute high-frequency electrical stimulation, which is sufficient to activate mTORC1 signaling in mouse muscle, does not increase muscle IGF-1 receptor, or PI3K p85 subunit, tyrosine phosphorylation, which are markers of IGF-1 receptor activation (Hamilton et al. 2010). Moreover, mice with a muscle-specific deletion of phosphatase and tensin homologue (PTEN), which should lead to an increase in the PI3K substrate phosphatidylinositol-3,4,5 trisphosphate (PIP3) and thus larger PI3K/Akt activation, had no greater SA-induced activation of mTORC1 signaling or muscle hypertrophy compared to wild-type mice (Hamilton et al. 2010). Finally, it was recently shown that the PI3K inhibitor, wortmanin, did not inhibit the early (24 h) SA-induced increase in skeletal muscle mTORC1 signaling (Miyazaki et al. 2011). Combined, these data strongly suggest that the initial mechanical stimuli-induced activation of mTORC1 signaling occurs in an IGF-1/PI3K/Akt-independent manner.

In summary, at least in rodent skeletal muscle, current evidence suggests that IGF-1 signaling does not play a significant role in the initial activation of mTORC1 signaling in response to mechanical stimuli. While there is some limited data from human studies that supports this contention [e.g., (Deldicque et al. 2008; West et al. 2009)], more research is required to establish that an IGF-1/PI3K/Akt-independent activation of mTORC1 signaling also occurs in human muscle in response to acute resistance exercise.

4.2 Extracellular Signal-Regulated Kinase 1/2 (ERK1/2)

ERK isoforms 1 and 2 are members of the large mitogen-activated protein kinase (MAPK) family and form part of the Ras/Raf/MEK/ERK1/2 signaling pathway (Morrison 2012). ERK1/2 signaling is activated under a range of conditions including growth factor stimulation (e.g., IGF-1) and various types of stresses, including mechanical stress (D'Angelo et al. 2011; Morrison 2012). Moreover, ERK1/2-mediated signaling has the potential to regulate a range of cellular processes, including cap-dependent translation initiation and elongation and ribosome biogenesis (Anjum and Blenis 2008). For example, ERK1/2 can phosphorylate the rDNA transcription factor UBF (Stefanovsky et al. 2001) and the MAPK-interacting kinases 1 and 2 (Mnk1 and Mnk2), which, in turn, phosphorylate eIF4E (Buxade et al. 2008). Furthermore, ERK1/2 phosphorylates and activates the 90 kDa ribosomal S6 kinases (p90^{RSK}). In turn, ERK1/2-activated p90^{RSK} has been shown to phosphorylate and regulate a range of protein synthesis-related factors, including eIF4B (Shahbazian et al. 2006), eEF2 kinase (Wang et al. 2001), rpS6 (Roux et al. 2007), the RNA polymerase I-specific transcription initiation factor, TIF-IA (Zhao et al. 2003), and GSK3 β (Stambolic and Woodgett 1994). Importantly, ERK1/2-activated p90^{RSK} signaling has also been shown to positively regulate mTORC1 activity via the phosphorylation of TSC2 and Raptor (Roux et al. 2004; Ma et al. 2005; Carrière et al. 2008; Fonseca et al. 2011). Therefore, ERK1/2/p90^{RSK} signaling has the potential to play an important role in the PI3K/Akt-independent activation of skeletal muscle mTORC1 signaling in response to mechanical overload/resistance exercise (Fig. 2).

ERK1/2 is known to be phosphorylated on the T202/Y204 residues, and thus activated, after various types of mechanical overload/resistance exercise in cultured cells, and in rodent and human skeletal muscle [e.g., (Martineau and Gardiner 2001; Drummond et al. 2009; Tannerstedt et al. 2009; Sasai et al. 2010; Miyazaki et al. 2011; Hulmi et al. 2012; You et al. 2012)]. While these studies suggest that ERK1/2 signaling could play a role in the mechanical activation of mTORC1 signaling, protein synthesis, and muscle hypertrophy, to date, only two studies have examined whether ERK1/2 signaling is necessary for these responses (Sasai et al. 2010; You et al. 2012). Firstly, Sasai et al. (2010) found that rapamycin, but not the MEK/ERK inhibitor, U0126, inhibited cyclic stretch-induced hypertrophy of cultured myotubes, indicating that mTORC1, and not ERK1/2, signaling was necessary for mechanically induced hypertrophy (Sasai et al. 2010). Secondly, You et al. (2012) used ex vivo passive stretch of isolated muscles to show that, while U0126 completely eliminated both basal and stretch-induced ERK1/2 T202/Y204 phosphorylation, and reduced basal p70^{S6K} T389 and 4E-BP1 T36/45 and S64 phosphorylation, it did not inhibit the magnitude of the stretch-induced increase in p70^{S6K} T389 or 4E-BP1 S64 phosphorylation (You et al. 2012). Thus, in the absence of ERK1/2 signaling, mechanical stimuli were still able to activate mTORC1 signaling (You et al. 2012). Furthermore, U0126 had no effect on either basal or stretch-induced rates of protein synthesis (You et al. 2012). Thus, at least in these stretch models, it appears that

ERK1/2 signaling is not necessary for the mechanically induced activation of mTORC1 signaling, protein synthesis, or muscle hypertrophy. Further in vivo research in rodents and humans is needed to confirm these findings.

4.3 Phosphatidic Acid (PA)

In 2001, the glycerophospholipid PA was found to activate mTOR signaling in a rapamycin-sensitive manner (Fang et al. 2001; Park et al. 2002). Since then, numerous studies have shown that the addition of exogenous PA to cultured cells, including muscle cells, is sufficient to activate mTORC1 signaling and increase protein synthesis in a PI3K/Akt-independent manner [e.g., (Foster 2007; O'Neil et al. 2009; You et al. 2012)]. Mechanistically, PA's ability to activate mTOR signaling has been shown to be due to its direct binding to mTOR's FRB domain and the subsequent activation of mTOR kinase activity (Fang et al. 2001; Veverka et al. 2008; You et al. 2012). Intracellular PA can be regulated by a number of different classes of enzymes that include phospholipase D (PLD), which synthesizes PA from phosphatidylcholine (PC); lysophosphatidic acid acyltransferases (LPAAT), which synthesize PA from lysophosphatidic acid (LPA); and the diacylglycerol kinases (DGK), which synthesize PA from diacylglycerol (DAG) (Wang et al. 2006; Foster 2007). Indeed, the overexpression of PLD1 (Jaafar et al. 2013), LPAAT0 (Tang et al. 2006), and DGK ζ (Avila-Flores et al. 2005) has been shown to be sufficient to activate mTORC1 signaling in various cell types. Alternatively, PA can also be controlled by enzymes that degrade PA, including A-type phospholipases (PLA), which convert PA to LPA, and phosphatidic acid phosphatases (PAP), which convert PA to DAG (Carman and Han 2006; Wang et al. 2006; Aoki et al. 2007).

To date, the role of PA produced by PLD1 has received the most investigation in regard to its potential role for regulating mTORC1 signaling and skeletal muscle mass. For example, PLD1 overexpression has been shown to induce hypertrophy of cultured myotubes, while the knockdown of PLD1 leads to a decrease in myotube size (Jaafar et al. 2013). Furthermore, the overexpression of PLD1 is sufficient to activate mTORC1 signaling and induce mouse skeletal muscle fiber hypertrophy in vivo (Jaafar et al. 2013). The first study to implicate PA in the mechanically induced activation of mTORC1 signaling in skeletal muscle showed that an increase in PA was sufficient to activate basal mTORC1 signaling, that passive stretch increased PLD activity and PA, and that the PLD inhibitor, 1-butanol, inhibited the stretch-induced increase in PA and mTORC1 signaling (Hornberger et al. 2006). Later studies also showed that in vivo eccentric contractions were also sufficient to increase muscle PA and that inhibiting the PLD-induced increase in PA with 1-butanol prevented the activation of mTORC1 signaling (O'Neil et al. 2009).

While these studies suggested that PLD1 played an important role in the mechanically induced activation of mTORC1 signaling, some investigators had questioned the specificity of 1-butanol as a PLD inhibitor. Specifically, recent studies had reported that many of the biological effects of 1-butanol could not be attributed to

the inhibition of the synthesis of PA by PLD (Su et al. 2009; Yanase et al. 2010; Sato et al. 2013). In light of this data, You et al. (2013) reexamined the role of PLD in the mechanically-induced increase in PA using a more specific PLD inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) (Su et al. 2009). Surprisingly, it was found that FIPI did not inhibit passive stretch-induced increases in PA or mTORC1 signaling, suggesting that PLD was in fact not necessary for these events (You et al. 2013). Instead, it was shown that passive stretch induced an increase in DAG, suggesting that there could be corresponding increases in DGK activity. Indeed, passive stretch was sufficient to increase membrane DGK activity, but further experiments showed that the α , β , γ , and θ isoforms of DGK were not necessary for the mechanically induced increase in PA and mTORC1 signaling (You et al. 2013). These findings then prompted the investigation of the potential role of DGK ζ , and using DGK ζ knockout mice, it was found that the passive stretch-induced increase in PA was almost completely abolished and mTORC1 signaling markedly impaired (You et al. 2013). Furthermore, the *in vivo* overexpression of DGK ζ was sufficient to induce muscle fiber hypertrophy in a kinase-dependent manner, and this hypertrophic response was largely inhibited by rapamycin (You et al. 2013). Combined, the results of this recent study strongly suggest that DGK ζ , and not PLD1 as previously thought, is largely responsible for the passive stretch-induced increase in PA and mTORC1 signaling. Further research is now required to confirm the role of DGK ζ in other models of mechanical stimulation (e.g., eccentric contractions and SA-induced chronic mechanical overload).

Overall, these data strongly suggest that PA plays an important role in the activation of mTORC1 signaling in response to mechanical stimuli. Moreover, the mechanically induced increase in PA may, in part, explain the previously observed PI3K/Akt-independent activation of mTORC1 (Fig. 2).

While mechanically induced increases in PA appear to play a significant role in the activation of mTORC1 signaling, several questions remain to be answered. For example, are mechanically induced increases in PA sufficient to increase protein synthesis in an mTORC1-dependent manner in skeletal muscle *in vivo*? Also, what is the upstream mechanically sensitive element(s) that induces an increase in PA? Finally, to date, all of the data regarding the role of PA in the mechanically induced activation of mTORC1 comes from rodent studies. Thus, more studies are needed to determine whether this proposed mechanism is conserved in human skeletal muscle.

4.4 Tuberlin (TSC2) Translocation and Ras Homologue Expressed in the Brain (Rheb) GTP-Loading Status

TSC2 and Rheb form part of the canonical insulin/IGF-1 signaling pathway, with Rheb being located immediately upstream of mTOR, while TSC2, in a complex with TSC1 (Hamartin), is located immediately upstream of Rheb (Fig. 2)




Fig. 3 Proposed molecular mechanisms for the mechanical activation of mTORC1 by changes in Rheb GTP-loading state and by amino acids. Emerging evidence suggests that mechanical overload/resistance exercise could (a) induce the translocation of late endosome/lysosome (LEL) membrane-bound tuberlin (TSC2) away from Ras homologue enriched in the brain (Rheb) GTPase, leading to an increase in Rheb GTP loading and the activation of mTORC1, or (b) induce a Rag GTPase-mediated translocation of mTORC1 to LEL membrane-bound Rheb that may also be accompanied by an increase in phosphatidic acid (PA) via a vacuolar sorting protein 34 (Vps34)-mediated translocation of phospholipase D1 (PLD1) to the LEL. See text for further details. Dotted lines (.....) indicate potential translocation events

(Huang and Manning 2008). Rheb is a GTP-binding protein that possesses GTPase activity, and its GTP/GDP-binding status is regulated by the GTPase activating protein (GAP) activity of TSC2 (Aspuria and Tamanoi 2004). Importantly, Rheb has been shown to interact with mTOR's catalytic domain, and when it is in its GTP-bound state, Rheb can directly activate mTOR kinase activity (Long et al. 2005; Sato et al. 2009). Thus, the current dogma proposes that under basal conditions, the GAP domain of TSC2 stimulates Rheb's intrinsic GTPase activity, which, in turn, converts active GTP-Rheb into inactive GDP-Rheb, leading to a repression of mTORC1 signaling (Inoki et al. 2003; Tee et al. 2003; Zhang et al. 2003). Conversely, when

stimulated by factors such as insulin, TSC2 GAP activity is proposed to be inhibited in a phosphorylation-dependent manner, leading to an increase in GTP-Rheb and the activation of mTORC1 signaling (Huang and Manning 2008).

In skeletal muscle, the overexpression of Rheb is sufficient to activate mTORC1 signaling, induce an increase in protein synthesis, and stimulate muscle fiber hypertrophy (Goodman et al. 2010, 2011b). Conversely, the depletion of Rheb in cultured myoblasts reduces mTORC1 signaling (Ge et al. 2011). Although relatively little is known regarding a possible role for TSC2 and Rheb in the mechanically induced activation of mTORC1 signaling in skeletal muscle, a recent study may have shed some light on this issue by suggesting that mechanical stimuli could regulate mTORC1 signaling, in part, by controlling the amount of GTP-Rheb (Jacobs et al. 2013b). In this study, it was shown that an acute bout of high-intensity eccentric contractions almost completely abolished the association of TSC2 with late endosomal/lysosomal (LEL) membrane structures (Jacobs et al. 2013b). Importantly, because a population of mTOR and Rheb is also found at LEL structures [e.g., (Saito et al. 2005; Sancak et al. 2008; Flinn et al. 2010; Yoon et al. 2011; Zhao et al. 2012; Jacobs et al. 2013b)], it is possible that mechanical stimuli could increase the amount of GTP-loaded Rheb, and thus mTORC1 signaling, by promoting the translocation of TSC2 away from LEL structures so that TSC2 can no longer act as a GAP toward Rheb (Fig. 3a). Furthermore, this mechanically induced translocation of TSC2 may be a phosphorylation-mediated event, although the kinase(s) responsible remains to be determined (Jacobs et al. 2013b). Thus, a mechanically induced translocation of TSC2 away from its GAP target Rheb could play an important role in the mechanically induced activation of mTORC1 signaling (Jacobs et al. 2013a) (Fig. 3a); however, whether this putative mechanism is PI3K/Akt independent remains to be determined. While this is an attractive hypothesis, significantly more work is required to confirm this mechanism in rodent muscle and to obtain evidence for such a mechanism in human skeletal muscle.

4.5 Amino Acids

It has long been known that mTOR signaling is regulated by amino acids, with amino acid depletion reducing mTOR signaling and increased amino acid availability leading to increased mTOR signaling [for a review, see (Jewell et al. 2013)]. However, it has only been relatively recently that the molecular mechanism behind the effect of amino acids has begun to be elucidated. For example, it was recently demonstrated in non-muscle cells that amino acids regulate the association of mTOR with LEL structures via a mechanism that is dependent on the Rag family of GTPases (Sancak et al. 2008, 2010). Specifically, it was shown that amino acid stimulation increases the association of mTOR with LEL structures by regulating the activity/GTP-loading state of the Rag GTPases [for a more comprehensive review of the role of Rag GTPases, see (Efeyan et al. 2012)]. Thus, it has been proposed that

amino acid-induced changes in mTORC1 signaling are primarily regulated by spatially controlling the ability of mTOR to interact with the LEL-associated activator, Rheb. Furthermore, PA could also play a role in amino acid-induced mTORC1 signaling. Indeed, a recent study has demonstrated that amino acids promote an increase in PLD1 activity and PLD1's association with the LEL and that PLD1 contributes to the amino acid-induced increases in mTORC1 signaling (Yoon et al. 2011). Thus, at least in cell culture models, the current evidence suggests that amino acids may control mTORC1 signaling by regulating both the association of mTOR with the LEL and the concentration of PA at the LEL (Fig. 3b).

In regard to skeletal muscle, it has long been known that exogenous amino acids are sufficient to induce an increase in protein synthesis in isolated muscles (Fulks et al. 1975) and that chronic mechanical overload induces an increase in the uptake of amino acids (Goldberg and Goodman 1969). More recently, amino acids (especially the branched-chain amino acid, leucine) have been shown to be sufficient to activate mTORC1 signaling and increase protein synthesis in rodent and human skeletal muscle in a rapamycin-sensitive manner [e.g., (Anthony et al. 2000; Dickinson et al. 2011)]. Thus, a mechanically induced uptake of amino acids could, in part, play a role in the mechanical activation of mTORC1 signaling in skeletal muscle. While there is certainly evidence that the ingestion of amino acids prior to, or immediately post, resistance exercise can potentiate the post-exercise increase in mTORC1 signaling and protein synthesis [for reviews, see (Blomstrand et al. 2006; Koopman et al. 2007; Drummond and Rasmussen 2008)], there is currently no direct evidence to support the hypothesis that amino acids are involved in the initial mechanically-induced activation of mTORC1. Nevertheless, it has recently been shown that an acute bout of resistance exercise that was sufficient to activate mTORC1 signaling also induced an increase in the leucine content of rat muscle (MacKenzie et al. 2007). Furthermore, this bout of resistance exercise increased the post-exercise activity of the class III PI3K, Vps34, which has been implicated in the amino acid-induced activation of PLD1 activity and mTORC1 signaling [e.g., (Gulati et al. 2008; Gran and Cameron-Smith 2011; Xu et al. 2011; Yoon et al. 2011)]. Thus, amino acids could potentially play a role in the mechanically induced PI3K/Akt-independent increase in mTORC1 signaling via the activation of PLD1 and an increase in PA synthesis (Fig. 3b). While promising, significantly more research is required to gain further insights into this hypothesis in both rodent and human skeletal muscle, and to reconcile this potential mechanism with the recent data suggesting that PLD1 does not play a role in the mechanically-induced activation of mTORC1 signaling (You et al. 2013).

4.6 Peroxynitrite-Induced Calcium Release

Previous studies in non-muscle cells have shown that mTORC1 signaling may be regulated by changes in intracellular calcium concentration ($[Ca^{2+}]_i$), with an increase in $[Ca^{2+}]_i$ activating mTORC1 signaling and a decrease in $[Ca^{2+}]_i$ leading to an inhibition of mTORC1 signaling (Graves et al. 1997; Conus et al. 1998).




Fig. 4 The proposed molecular mechanism for the mechanical activation of mTORC1 by peroxynitrite-induced Ca^{2+} release. Recent evidence suggests that mechanical stimuli induce a rapid and transient activation of neuronal nitric oxide synthase (nNOS) activity and an increase in nitric oxide (NO) production. This mechanically induced NO is proposed to react with NADPH oxidase 4 (Nox4)-derived superoxide (O_2^-) to form peroxynitrite (ONOO^-), which, in turn, induces calcium (Ca^{2+}) release from sarcoplasmic reticulum (SR)-transient receptor potential cation channel subfamily V (TrpV1) channels, leading to the activation of mTORC1. See text for further details

Furthermore, depending on the conditions, changes in the cellular redox state have been shown to both positively and negatively regulate mTORC1 signaling (Corradetti and Guan 2006). Importantly, it is well known that mechanical stimulation of skeletal muscle results in increases in $[\text{Ca}^{2+}]_i$ and a change in the cellular redox state via the production of reactive oxygen species [ROS; e.g., superoxide (O_2^-) and hydrogen peroxide (H_2O_2)] and reactive nitrogen species [RNS; e.g., nitric oxide (NO) and peroxynitrite (ONOO^-)] [for reviews, see (Allen et al. 2008; Powers and Jackson 2008; Baylor and Hollingworth 2012; McConell et al. 2012)]. Thus, it is possible that increases in $[\text{Ca}^{2+}]_i$ and/or ROS/RNS may play a role in the mechanical activation of mTORC1 signaling and muscle hypertrophy. In support of this hypothesis, NO has been shown to play a role in mechanical overload-induced skeletal muscle hypertrophy, with the nitric oxide synthase (NOS) inhibitor, L-NAME, being sufficient to inhibit SA-induced muscle hypertrophy in rats (Smith et al. 2002; Soltow et al. 2006); however, against this hypothesis, one study has reported that the Ca^{2+} chelator, BAPTA-AM, did not inhibit passive stretch-induced mTORC1 signaling in isolated skeletal muscles (Hornberger et al. 2006).

More recently, a direct link between ROS/RNS, $[\text{Ca}^{2+}]_i$, mTOR signaling, and mechanically induced skeletal muscle hypertrophy was proposed by Ito

et al. (2013a, b). Specifically, evidence was obtained for a mechanism whereby the initiation of chronic mechanical loading of skeletal muscle induces a rapid and transient (within minutes) increase in nNOS-derived NO, which reacts with NADPH oxidase 4 (Nox4)-derived O_2^- to form ONOO^- . This mechanically-induced ONOO^- , in turn, induces an increase in $[\text{Ca}^{2+}]_i$ via the activation of sarcoplasmic reticulum-located transient receptor potential cation channel subfamily V (TrpV1) channels, which leads to the activation of mTORC1 signaling and a subsequent hypertrophic response over 7 days (Fig. 4) (Ito et al. 2013a, b). The results of this study open up an exciting new field of investigation in the pursuit of identifying the mechanism(s) that regulate the activation of mTORC1 signaling in response to mechanical overload or resistance exercise. However, further studies are required to confirm the many aspects of this proposed mechanism and, particularly, to determine how an increase in $[\text{Ca}^{2+}]_i$ activates mTORC1 signaling. Moreover, further work is required to reconcile this mechanism with previous work that suggests that Ca^{2+} does not play a role in the mechanically induced activation of mTORC1 signaling (Hornberger et al. 2006). Finally, it needs to be determined whether this mechanism is only relevant for the chronic overload model or whether it is also active during an acute bout of resistance exercise in rodents and humans.

In summary, there are currently several putative mechanisms that may be responsible for the activation of mTORC1 signaling by increased mechanical loading or resistance exercise (Figs. 2, 3, and 4). To date, significant evidence is mounting to suggest that the IGF-1/PI3K/Akt pathway does not play a significant role in the mechanically induced activation of mTORC1. Furthermore, very limited evidence also suggests that ERK1/2 signaling may not be involved in this process. Of the remaining potential mechanisms, a mechanically induced increase in PA has so far received the most experimental support, while limited, but promising, data suggests possible roles for mechanically induced increases in amino acids and TSC2 translocation-mediated increases in GTP-Rheb. Finally, the most recent hypothesis implicates mechanically induced increases in ONOO^- and a subsequent Ca^{2+} -induced activation of mTORC1 signaling. Further research is required to determine whether one particular mechanism plays a dominant role under different mechanical loading conditions or whether there is a degree of synergism or redundancy between them.

5 Conclusion

Since the discovery of rapamycin and mTOR, there has been a huge expansion in our knowledge of the mechanisms that regulate cell growth, including muscle cell growth. Moreover, these advances have enabled the discovery of the important role that mTORC1 signaling plays in the regulation of protein synthesis and skeletal muscle mass in response to mechanical overload/resistance-type exercise. However, despite these advances, there are still many questions that need to be answered. For example, is mTORC1 signaling necessary for resistance training-

induced muscle hypertrophy in humans? Does mTORC1 signaling play a role in the acute responses and chronic adaptations to endurance or sprint exercise? To what extent, if any, does mTORC1 play a role in the regulation of basal/resting skeletal muscle protein synthesis and mass? What are the specific roles of 4E-BP1 and p70^{S6K1}, and their associated downstream targets, in mechanical stimuli-induced increases in protein synthesis and muscle mass? What are the mechanically sensitive upstream molecular mechanisms that regulate mTORC1 signaling? Based on these questions, it is clear that significantly more research is required to fully elucidate the many roles of mTORC1 signaling in skeletal muscle and, in particular, its role in the regulation of protein synthesis and skeletal muscle hypertrophy in response to different forms of mechanical stimuli. Ultimately, the answers to these questions will help in the development of more effective exercise programming and in the potential development of pharmacological interventions aimed at preventing/attenuating the loss of, or increasing, skeletal muscle mass.

Acknowledgments This work was supported by the National Institutes of Health grant AR063256.

References

- Adams GR (1998) Role of insulin-like growth factor-I in the regulation of skeletal muscle adaptation to increased loading. *Exerc Sport Sci Rev* 26:31–60
- Adams GR, Bamman MM (2012) Characterization and regulation of mechanical loading-induced compensatory muscle hypertrophy. *Compr Physiol* 2:2829–2870
- Adams GR, Haddad F (1996) The relationships among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. *J Appl Physiol* 81:2509–2516
- Aguilar V, Alliouachene S, Sotiropoulos A et al (2007) S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. *Cell Metab* 5:476–487
- Alayev A, Holz MK (2013) mTOR signaling for biological control and cancer. *J Cell Physiol* 228:1658–1664
- Alessi DR, Kozlowski MT, Weng Q-P, Morrice N, Avruch J (1998) 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. *Curr Biol* 8:69–81
- Allen DG, Lamb GD, Westerblad H (2008) Impaired calcium release during fatigue. *J Appl Physiol* 104:296–305
- Alway SE (1997) Overload-induced C-Myc oncoprotein is reduced in aged skeletal muscle. *J Gerontol A Biol Sci Med Sci* 52:B203–B211
- Anjum R, Blenis J (2008) The RSK family of kinases: emerging roles in cellular signalling. *Nat Rev Mol Cell Biol* 9:747–758
- Anthony JC, Yoshizawa F, Anthony TG, Vary TC, Jefferson LS, Kimball SR (2000) Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a Rapamycin-sensitive pathway. *J Nutr* 130:2413–2419
- Anthony TG, McDaniel BJ, Knoll P, Bunpo P, Paul GL, McNurlan MA (2007) Feeding meals containing soy or whey protein after exercise stimulates protein synthesis and translation initiation in the skeletal muscle of male rats. *J Nutr* 137:357–362
- Aoki J, Inoue A, Makide K, Saiki N, Arai H (2007) Structure and function of extracellular phospholipase A1 belonging to the pancreatic lipase gene family. *Biochimie* 89:197–204
- Appenzeller-Herzog C, Hall MN (2012) Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. *Trends Cell Biol* 22:274–282
- Armstrong DD, Esser KA (2005) Wnt/ β -catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy. *Am J Physiol Cell Physiol* 289:C853–C859
- Aspura PJ, Tamanoi F (2004) The Rheb family of GTP-binding proteins. *Cell Signal* 16:1105–1112
- Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H (2005) Selective activation of AMPK-PGC-1 α or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. *FASEB J* 19:786–788
- Avila-Flores A, Santos T, Rincon E, Merida I (2005) Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. *J Biol Chem* 280:10091–10099
- Azpiroz I, Saltiel AR, DePaoli-Roach AA, Lawrence CJ (1996) Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and Rapamycin-sensitive pathways. *J Biol Chem* 271:5033–5039
- Baar K, Esser K (1999) Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise. *Am J Physiol* 276:C120–C127
- Bachmann RA, Kim J-H, Wu A-L, Park I-H, Chen J (2006) A nuclear transport signal in mammalian target of Rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. *J Biol Chem* 281:7357–7363
- Baker H, Sidorowicz A, Sehgal SN, Vezina C (1978) Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. *J Antibiot (Tokyo)* 31:539–545
- Bandi HR, Ferrari S, Krieg J, Meyer HE, Thomas G (1993) Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3 T3 fibroblasts stimulated with serum. *J Biol Chem* 268:4530–4533
- Banerjee P, Ahmad MF, Grove JR, Kozlosky C, Price DJ, Avruch J (1990) Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. *Proc Natl Acad Sci U S A* 87:8550–8554
- Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL (1998) Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. *Proc Natl Acad Sci U S A* 95:15603–15607
- Baylor SM, Hollingworth S (2012) Intracellular calcium movements during excitation-contraction coupling in mammalian slow-twitch and fast-twitch muscle fibers. *J Gen Physiol* 139:261–272
- Beelen M, Zorenc A, Pennings B, Senden JM, Kuipers H, van Loon LJC (2011) Impact of protein coingestion on muscle protein synthesis during continuous endurance type exercise. *Am J Physiol – Endocrinol Metab* 300:E945–E954
- Belsham GJ, Denton RM (1980) The effect of insulin and adrenaline on the phosphorylation of a 22 000-molecular weight protein within isolated fat cells; possible identification as the inhibitor-1 of the 'general phosphatase' [proceedings]. *Biochem Soc Trans* 8:382–383
- Ben-Sahra I, Howell JJ, Asara JM, Manning BD (2013) Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. *Science* 339:1323–1328
- Bentzinger CF, Romanino K, Cloëtta D et al (2008) Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. *Cell Metab* 8:411–424
- Bentzinger C, Lin S, Romanino K et al (2013) Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. *Skeletal Muscle* 3:6
- Benziane B, Burton TJ, Scanlan B et al (2008) Divergent cell signaling after short-term intensified endurance training in human skeletal muscle. *Am J Physiol – Endocrinol Metab* 295:E1427–E1438
- Berdeaux R, Stewart R (2012) cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration. *Am J Physiol – Endocrinol Metab* 303:E1–E17
- Blenis J, Chung J, Erikson E, Alcorta D, Erikson R (1991) Distinct mechanisms for the activation of the RSK kinases/MAP2 kinase/pp90rsk and pp70–S6 kinase signaling systems are indicated by inhibition of protein synthesis. *Cell Growth Differ* 2:279–285
- Blomstrand E, Eliasson J, Karlsson HKR, Köhnke R (2006) Branched-chain amino acids activate key enzymes in protein synthesis after physical exercise. *J Nutr* 136:269S–273S

- Bodine SC (2006) mTOR signaling and the molecular adaptation to resistance exercise. *Med Sci Sports Exerc* 38:1950–1957
- Bodine SC, Stitt TN, Gonzalez M et al (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. *Nat Cell Biol* 3:1014–1019
- Booth FW, Nicholson WF, Watson PA (1982) Influence of muscle use on protein synthesis and degradation. *Exerc Sport Sci Rev* 10:27–48
- Brown EJ, Albers MW, Bum Shin T, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. *Nature* 369:756–758
- Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL (1995) Control of p70 s6 kinase by kinase activity of FRAP in vivo. *Nature* 377:441–446
- Brunn GJ, Fadden P, Haystead TAJ, Lawrence JC (1997a) The mammalian target of Rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. *J Biol Chem* 272:32547–32550
- Brunn GJ, Hudson CC, Sekulić A et al (1997b) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. *Science* 277:99–101
- Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. *Proc Natl Acad Sci U S A* 95:1432–1437
- Burry M, Hawkins D, Spangenburg EE (2007) Lengthening contractions differentially affect p70 (s6k) phosphorylation compared to isometric contractions in rat skeletal muscle. *Eur J Appl Physiol* 100:409–415
- Bush JA, Kimball SR, O'Connor PMJ et al (2003) Translational control of protein synthesis in muscle and liver of growth hormone-treated pigs. *Endocrinology* 144:1273–1283
- Buxade M, Parra-Palau JL, Proud CG (2008) The Mnk: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). *Front Biosci* 13:5359–5373
- Camera DM, Edge J, Short MJ, Hawley JA, Coffey VG (2010) Early time course of Akt phosphorylation after endurance and resistance exercise. *Med Sci Sports Exerc* 42:1843–1852
- Carman GM, Han G-S (2006) Roles of phosphatidate phosphatase enzymes in lipid metabolism. *Trends Biochem Sci* 31:694–699
- Carraro F, Stuart CA, Hartl WH, Rosenblatt J, Wolfe RR (1990) Effect of exercise and recovery on muscle protein synthesis in human subjects. *Am J Physiol* 259:E470–E476
- Carrière A, Cargnello M, Julien L-A, Gao H, Bonnell E, Thibault P, Roux PP (2008) Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. *Curr Biol* 18:1269–1277
- Chauvin C, Koka V, Nouschi A et al (2013) Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. *Oncogene*, in press, doi: 10.1038/nc.2012.606
- Chen J, Zheng XF, Brown EJ, Schreiber SL (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. *Proc Natl Acad Sci U S A* 92:4947–4951
- Chesley A, MacDougall JD, Tarnopolsky MA, Atkinson SA, Smith K (1992) Changes in human muscle protein synthesis after resistance exercise. *J Appl Physiol* 73:1383–1388
- Chiu MI, Katz H, Berlin V (1994) RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. *Proc Natl Acad Sci U S A* 91:12574–12578
- Choo AY, Yoon S-O, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. *Proc Natl Acad Sci U S A* 105:17414–17419
- Chung J, Kuo CJ, Crabtree GR, Blenis J (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. *Cell* 69:1227–1236
- Coffey VG, Zhong Z, Shield A, Canny BJ, Chibalin AV, Zierath JR, Hawley JA (2006) Early signaling responses to divergent exercise stimuli in skeletal muscle from well-trained humans. *FASEB J* 20:190–192
- Coffey VG, Moore DR, Burd NA et al (2011) Nutrient provision increases signalling and protein synthesis in human skeletal muscle after repeated sprints. *Eur J Appl Physiol* 111:1473–1483
- Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ (1995) Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. *J Biol Chem* 270:12109–12116

- Conus NM, Hemmings BA, Pearson RB (1998) Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70S6k. *J Biol Chem* 273:4776–4782
- Corradetti MN, Guan KL (2006) Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? *Oncogene* 25:6347–6360
- Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1 α transcriptional complex. *Nature* 450:736–740
- Cureton KJ, Collins MA, Hill DW, McElhannon FM Jr (1988) Muscle hypertrophy in men and women. *Med Sci Sports Exerc* 20:338–344
- Cuthbertson DJ, Babraj J, Smith K, Wilkes E, Fedele MJ, Esser K, Rennie M (2006) Anabolic signaling and protein synthesis in human skeletal muscle after dynamic shortening or lengthening exercise. *Am J Physiol Endocrinol Metab* 290:E731–E738
- Czerwinski SM, Martin JM, Bechtel PJ (1994) Modulation of IGF mRNA abundance during stretch-induced skeletal muscle hypertrophy and regression. *J Appl Physiol* 76:2026–2030
- D'Angelo F, Tiribuzi R, Armentano I, Kenny JM, Martino S, Orlacchio A (2011) Mechanotransduction: tuning stem cells fate. *J Funct Biomater* 2:67–87
- Dardevet D, Sornet C, Vary T, Grizard J (1996) Phosphatidylinositol 3-kinase and p70 s6 kinase participate in the regulation of protein turnover in skeletal muscle by insulin and insulin-like growth factor I. *Endocrinology* 137:4087–4094
- De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. *Oncogene* 23:3189–3199
- Dearth CL, Goh Q, Marino JS et al (2013) Skeletal muscle cells express ICAM-1 after muscle overload and ICAM-1 contributes to the ensuing hypertrophic response. *PLoS One* 8:e58486
- Deldicque L, Louis M, Theisen D et al (2005) Increased IGF mRNA in human skeletal muscle after creatine supplementation. *Med Sci Sports Exerc* 37:731–736
- Deldicque L, Atherton P, Patel R, Theisen D, Nielens H, Rennie M, Francaux M (2008) Decrease in Akt/PKB signalling in human skeletal muscle by resistance exercise. *Eur J Appl Physiol* 104:57–65
- Dennis PB, Pullen N, Kozma SC, Thomas G (1996) The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. *Mol Cell Biol* 16:6242–6251
- Desai BN, Myers BR, Schreiber SL (2002) FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. *Proc Natl Acad Sci U S A* 99:4319–4324
- DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ (1990) Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. *Am J Physiol* 259:E89–E95
- Dickinson JM, Fry CS, Drummond MJ et al (2011) Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids. *J Nutr* 141:856–862
- Dickinson JM, Drummond MJ, Fry CS et al (2013) Rapamycin does not affect post-absorptive protein metabolism in human skeletal muscle. *Metabolism* 62:144–151
- DiPasquale DM, Cheng M, Billich W, Huang SA, van Rooijen N, Hornberger TA, Koh TJ (2007) Urokinase-type plasminogen activator and macrophages are required for skeletal muscle hypertrophy in mice. *Am J Physiol Cell Physiol* 293:C1278–C1285
- Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M (2006) S6K1- and ITRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. *Science* 314:467–471
- Dos DS, Ali SM, Kim D-H et al (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 14:1296–1302
- Drake JC, Peelor FF, Biela LM, Watkins MK, Miller RA, Hamilton KL, Miller BF (2013) Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. *J Gerontol A Biol Sci Med Sci* 68:1493–1501

- Drenan RM, Liu X, Bertram PG, Zheng XFS (2004) FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. *J Biol Chem* 279:772–778
- Dreyer HC, Fujita S, Cadenas JG, Chinkes DL, Volpi E, Rasmussen BB (2006) Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. *J Physiol* 576:613–624
- Dreyer HC, Drummond MJ, Pennings B et al (2008) Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. *Am J Physiol – Endocrinol Metab* 294:E392–E400
- Drummond MJ, Rasmussen BB (2008) Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis. *Curr Opin Clin Nutr Metab Care* 11:222–226
- Drummond MJ, Fry CS, Glynn EL et al (2009) Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. *J Physiol* 587:1535–1546
- Duan S, Skaar Jeffrey A, R, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, Pagano M (2011) mTOR generates an auto-amplification loop by triggering the β TrCP- and CK1 α -dependent degradation of DEPTOR. *Mol Cell* 44:317–324
- Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F (2012) Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. *Cell Mol Life Sci* 69:1651–1667
- Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH (1990) Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. *J Immunol* 144:251–258
- Edgett BA, Fortner ML, Bonen A, Gurd BJ (2013) Mammalian target of rapamycin pathway is up-regulated by both acute endurance exercise and chronic muscle contraction in rat skeletal muscle. *Appl Physiol Nutr Metab* 38:862–869
- Efeyan A, Zoncu R, Sabatini DM (2012) Amino acids and mTORC1: from lysosomes to disease. *Trends Mol Med* 18:524–533
- Eliasson J, Elfegoun T, Nilsson J, Kohnke R, Ekblom B, Blomstrand E (2006) Maximal lengthening contractions increase p70 S6 kinase phosphorylation in human skeletal muscle in the absence of nutritional supply. *Am J Physiol Endocrinol Metab* 291:E1197–E1205
- Esbjörnsson M, Rundqvist HC, Mascher H, Österlund T, Rooyackers O, Blomstrand E, Jansson E (2012) Sprint exercise enhances skeletal muscle p70S6k phosphorylation and more so in women than in men. *Acta Physiol* 205:411–422
- Fadden P, Haystead TAJ, Lawrence JCL Jr (1997) Identification of phosphorylation sites in the translational regulator, p70S6, that are controlled by insulin and rapamycin in rat adipocytes. *J Biol Chem* 272:10240–10247
- Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. *Science* 294:1942–1945
- Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. *PLoS Biol* 7:e1000038
- Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G (1991) Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. *J Biol Chem* 266:22770–22775
- Flinn RJ, Yan Y, Goswami S, Parker PJ, Backer JM (2010) The late endosome is essential for mTORC1 signaling. *Mol Biol Cell* 21:833–841
- Fluckey JD, Knox M, Smith L, Dupont-Versteegden EE, Gaddy D, Tesch PA, Peterson CA (2006) Insulin-facilitated increase of muscle protein synthesis after resistance exercise involves a MAP kinase pathway. *Am J Physiol* 290:E1205–E1211
- Fok WC, Zhang Y, Salmon AB et al (2013) Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice. *J Gerontol A Biol Sci Med Sci* 68:108–116

- Fonseca BD, Alain T, Finestone LK et al (2011) Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK), extracellular signal-regulated kinase (ERK), and p90RSK in the control of mTORC1 protein signaling by phorbol esters. *J Biol Chem* 286:27111–27122
- Fornaro M, Hinken AC, Needle S et al (2013) Mechano growth factor peptide (MGF) has no apparent effect on muscle myoblasts or primary muscle stem cells. *Am J Physiol Endocrinol Metab*, in press, doi: 10.1152/ajpendo.00408.2013
- Foster DA (2007) Regulation of mTOR by phosphatidic acid? *Cancer Res* 67:1–4
- Frey JW, Farley EE, O'Neil TK, Burkholder TJ, Hornberger TA (2009) Evidence that mechanosensors with distinct biomechanical properties allow for specificity in mechanotransduction. *Biophys J* 97:347–356
- Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. *Curr Biol* 16:1865–1870
- Frost RA, Lang CH (1999) Differential effects of insulin-like growth factor I (IGF-I) and IGF-binding protein-1 on protein metabolism in human skeletal muscle cells. *Endocrinology* 140:3962–3970
- Frost RA, Lang CH (2007) Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. *J Appl Physiol* 103:378–387
- Frost RA, Lang CH (2011) mTOR signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong? *Physiology* 26:83–96
- Fulks RM, Li JB, Goldberg AL (1975) Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm. *J Biol Chem* 250:290–298
- Gallagher JW, Kubica N, Kimball SR, Jefferson LS (2008) Reduced eukaryotic initiation factor 2B β -subunit expression suppresses the transformed phenotype of cells overexpressing the protein. *Cancer Res* 68:8752–8760
- Gao D, Inuzuka H, Tan MK et al (2011) mTOR drives its own activation via SCF β TrCP-dependent degradation of the mTOR inhibitor DEPTOR. *Mol Cell* 44:290–303
- García-martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *Biochem J* 416:375–385
- Gautsch TA, Anthony JC, Kimball SR, Paul GL, Layman DK, Jefferson LS (1998) Availability of eIF4E regulates skeletal muscle protein synthesis during recovery from exercise. *Am J Physiol* 274:C406–C414
- Ge Y, Yoon M-S, Chen J (2011) Raptor and Rheb negatively regulate skeletal myogenesis through suppression of insulin receptor substrate 1 (IRS1). *J Biol Chem* 286:35675–35682
- Gibala MJ, McGee SL, Garnham AP, Howlett KF, Snow RJ, Hargreaves M (2009) Brief intense interval exercise activates AMPK and p38 MAPK signaling and increases the expression of PGC-1 α in human skeletal muscle. *J Appl Physiol* 106:929–934
- Gilligan M, Welsh GI, Flynn A et al (1996) Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. *J Biol Chem* 271:2121–2125
- Gingras A-C, Gygi SP, Raught B et al (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. *Genes Dev* 13:1422–1437
- Glass DJ (2010) PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. *Curr Top Microbiol Immunol* 346
- Glover EI, Oates BR, Tang JE, Moore DR, Tarnopolsky MA, Phillips SM (2008) Resistance exercise decreases eIF2B ϵ phosphorylation and potentiates the feeding-induced stimulation of p70S6K1 and rpS6 in young men. *Am J Physiol Regul Integr Comp Physiol* 295:R604–R610
- Goldberg AL (1967) Work-induced growth of skeletal muscle in normal and hypophysectomized rats. *Am J Physiol* 213:1193–1198

- Goldberg AL (1968a) Protein synthesis during work-induced growth of skeletal muscle. *J Cell Biol* 36:653–658
- Goldberg AL (1968b) Role of insulin in work-induced growth of skeletal muscle. *Endocrinology* 83:1071–1073
- Goldberg AL, Goodman HM (1969) Amino acid transport during work-induced growth of skeletal muscle. *Am J Physiol* 216:1111–1115
- Goldberg AL, Etlinger JD, Goldspink DF, Jablecki C (1975) Mechanism of work-induced hypertrophy of the skeletal muscle. *Med Sci Sports* 7:185–198
- Goldspink DF, Cox VM, Smith SK, Eaves LA, Osbaldeston NJ, Lee DM, Mantle D (1995) Muscle growth in response to mechanical stimuli. *Am J Physiol* 268:E288–E297
- Goncharova EA, Goncharov DA, Li H, Pimpong W, Lu S, Khavin I, Krymskaya VP (2011) mTORC2 is required for proliferation and survival of TSC2-null cells. *Mol Cell Biol* 31:2484–2498
- Goodman CA, Miu MH, Frey JW et al (2010) A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of rapamycin signaling is sufficient to induce skeletal muscle hypertrophy. *Mol Biol Cell* 21:3258–3268
- Goodman CA, Frey JW, Mabrey DM, Jacobs BL, Lincoln HC, You J-S, Hornberger TA (2011a) The role of skeletal muscle mTOR in the regulation of mechanical load-induced growth. *J Physiol* 589:5485–5501
- Goodman CA, Mabrey DM, Frey JW, Miu MH, Schmidt EK, Pierre P, Hornberger TA (2011b) Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. *FASEB J* 25:1028–1039
- Goodman CA, Mayhew DL, Hornberger TA (2011c) Recent progress towards understanding the molecular mechanisms that regulate skeletal muscle mass. *Cell Signal* 23:1896–1906
- Gran P, Cameron-Smith D (2011) The actions of exogenous leucine on mTOR signalling and amino acid transporters in human myotubes. *BMC Physiol* 11:10
- Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA, Lawrence JC (1995) cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. *Proc Natl Acad Sci U S A* 92:7222–7226
- Graves LM, He Y, Lambert J, Hunter D, Li X, Earp HS (1997) An intracellular calcium signal activates p70 but not p90 ribosomal S6 kinase in liver epithelial cells. *J Biol Chem* 272:1920–1928
- Guertin DA, Stevens DM, Thoreen CC et al (2006) Ablation in mice of the mTORC components raptor, rictor, or mTORC2 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC [alpha], but not S6K1. *Dev Cell* 11:859–871
- Gulati P, Gaspers LD, Dann SG et al (2008) Amino acids activate mTOR complex 1 via Ca²⁺/CaM signaling to hVps34. *Cell Metab* 7:456–465
- Gulve EA, Dice JF (1989) Regulation of protein synthesis and degradation in L8 myotubes. Effects of serum, insulin and insulin-like growth factors. *Biochem J* 260:377–387
- Haar EV, S-i L, Bandhakavi S, Griffin TJ, Kim D-H (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. *Nat Cell Biol* 9:316–323
- Hall MN (2013) On mTOR nomenclature. *Biochem Soc Trans* 41:887–888
- Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD (2003) Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. *J Physiol* 547:247–254
- Hamilton DL, Philp A, MacKenzie MG, Baar K (2010) A limited role for PI(3,4,5)P₃ regulation in controlling skeletal muscle mass in response to resistance exercise. *PLoS One* 5:e11624
- Hannan KM, Brandenburger Y, Jenkins A et al (2003) mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF[dagger]. *Mol Cell Biol* 23:8862–8877
- Hara K, Maruki Y, Long X et al (2002) Raptor, a binding partner of target of Rapamycin (TOR), mediates TOR action. *Cell* 110:177–189

- Harber MP, Crane JD, Dickinson JM, Jemiolo B, Raue U, Trappe TA, Trappe SW (2009a) Protein synthesis and the expression of growth-related genes are altered by running in human vastus lateralis and soleus muscles. *Am J Physiol Regul Integr Comp Physiol* 296:R708–R714
- Harber MP, Konopka AR, Douglass MD, Minchev K, Kaminsky LA, Trappe TA, Trappe S (2009b) Aerobic exercise training improves whole muscle and single myofiber size and function in older women. *Am J Physiol Regul Integr Comp Physiol* 297:R1452–R1459
- Harber MP, Konopka AR, Jemiolo B, Trappe SW, Trappe TA, Reidy PT (2010) Muscle protein synthesis and gene expression during recovery from aerobic exercise in the fasted and fed states. *Am J Physiol – Regul, Integr Comp Physiol* 299:R1254–R1262
- Harding MW, Galat A, Uehling DE, Schreiber SL (1989) A receptor for the immuno-suppressant FK506 is a cis-trans peptidyl-prolyl isomerase. *Nature* 341:758–760
- Haselbacher GK, Humbel RE, Thomas G (1979) Insulin-like growth factor: insulin or serum increase phosphorylation of ribosomal protein S6 during transition of stationary chick embryo fibroblasts into early G1 phase of the cell cycle. *FEBS Lett* 100:185–190
- Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science* 253:905–909
- Hill M, Wernig A, Goldspink G (2003) Muscle satellite (stem) cell activation during local tissue injury and repair. *J Anat* 203:89–99
- Hinnebusch AG, Lorsch JR (2012) The mechanism of eukaryotic translation initiation: new insights and challenges. *Cold Spring Harb Perspect Biol* 4:pil: a011544
- Holm L, van Hall G, Rose AJ, Miller BF, Doessing S, Richter EA, Kjaer M (2010) Contraction intensity and feeding affect collagen and myofibrillar protein synthesis rates differently in human skeletal muscle. *Am J Physiol Endocrinol Metab* 298:E257–E269
- Holz MK, Ballif BA, Gygi SP, Blenis J (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell* 123:569–580
- Hornberger TA, Chien S (2006) Mechanical stimuli and nutrients regulate rapamycin-sensitive signaling through distinct mechanisms in skeletal muscle. *J Cell Biochem* 97:1207–1216
- Hornberger TA, McLoughlin TJ, Leszczynski JK et al (2003) Selenoprotein-deficient transgenic mice exhibit enhanced exercise-induced muscle growth. *J Nutr* 133:3091–3097
- Hornberger TA, Stuppard R, Conley KE, Fedele MJ, Fiorotto ML, Chin ER, Esser KA (2004) Mechanical stimuli regulate rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase B- and growth factor-independent mechanism. *Biochem J* 380:795–804
- Hornberger TA, Armstrong DD, Koh TJ, Burkholder TJ, Esser KA (2005a) Intracellular signaling specificity in response to uniaxial vs. multiaxial stretch: implications for mechanotransduction. *Am J Physiol Cell Physiol* 288:C185–C194
- Hornberger TA, Mateja RD, Chin ER, Andrews JL, Esser KA (2005b) Aging does not alter the mechanosensitivity of the p38, p70S6k, and JNK2 signaling pathways in skeletal muscle. *J Appl Physiol* 98:1562–1566
- Hornberger TA, Chu WK, Mak YW, Hsiung JW, Huang SA, Chien S (2006) The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. *Proc Natl Acad Sci U S A* 103:4741–4746
- Hu C, Pang S, Kong X, Velleca M, Lawrence JC (1994) Molecular cloning and tissue distribution of PHAS-I, an intracellular target for insulin and growth factors. *Proc Natl Acad Sci U S A* 91:3730–3734
- Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. *Biochem J* 412:179–190
- Huang Z, Chen X, Chen D (2011) Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. *Cell Signal* 23:1441–1446
- Hudelmaier M, Wirth W, Himmer M, Ring-Dimitriou S, Sanger A, Eckstein F (2010) Effect of exercise intervention on thigh muscle volume and anatomical cross-sectional areas – quantitative assessment using MRI. *Magn Reson Med* 64:1713–1720
- Hulmi JJ, Walker S, Ahtiaainen JP, Nyman K, Kraemer WJ, Hakkinen K (2012) Molecular signaling in muscle is affected by the specificity of resistance exercise protocol. *Scand J Med Sci Sports* 22:240–248

- Huo Y, Iadevaia V, Yao Z et al (2012) Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis. *Biochem J* 444:141–151
- Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev* 17:1829–1834
- Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda Si (2013a) Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. *Nat Med* 19:101–106
- Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda Si (2013b) Capsaicin mimics mechanical load-induced intracellular signaling events: involvement of TRPV1-mediated calcium signaling in induction of skeletal muscle hypertrophy. *Channels* 7:221–224
- Izumiya Y, Hopkins T, Morris C et al (2008) Fast/glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. *Cell Metab* 7:159–172
- Jaafar R, De Larichaudy J, Chanon S et al (2013) Phospholipase D regulates the size of skeletal muscle cells through the activation of mTOR signaling. *Cell Commun Signal* 11:55
- Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat Cell Biol* 6:1122–1128
- Jacobs BL, Goodman CA, Hornberger TA (2013a) The mechanical activation of mTOR signaling: an emerging role for late endosome/lysosomal targeting. *J Muscle Res Cell Motil*, in press, doi: 10.1007/s10974-013-9367-4
- Jacobs BL, You J-S, Frey JW, Goodman CA, Gundermann DM, Hornberger TA (2013b) Eccentric contractions increase TSC2 phosphorylation and alter the targeting of TSC2 and mTOR to the lysosome. *J Physiol* 591:4611–4620
- Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB (2007) Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. *Growth Factors* 25:209–226
- Jefferies HB, Reinhard C, Kozma SC, Thomas G (1994) Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. *Proc Natl Acad Sci U S A* 91:4441–4445
- Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G (1997) Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. *EMBO J* 16:3693–3704
- Jewell JL, Russell RC, Guan K-L (2013) Amino acid signalling upstream of mTOR. *Nat Rev Mol Cell Biol* 14:133–139
- Jung CH, Ro S-H, Cao J, Otto NM, Kim D-H (2010) mTOR regulation of autophagy. *FEBS Lett* 584:1287–1295
- Jungwon C, Chen J, Schreiber SL, Jon C (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. *Science* 273:239–242
- Kang SA, Pacold ME, Cervantes CL et al (2013) mTORC1 phosphorylation sites encode their sensitivity to starvation and Rapamycin. *Science* 341
- Kantidakis T, Ramsbottom BA, Birch JL, Dowding SN, White RJ (2010) mTOR associates with TFIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. *Proc Natl Acad Sci U S A* 107:11823–11828
- Kelen KVD, Beyaert R, Inze D, Veylder LD (2009) Translational control of eukaryotic gene expression. *Crit Rev Biochem Mol Biol* 44:143–168
- Kim JE, Chen J (2000) Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. *Proc Natl Acad Sci U S A* 97:14340–14345
- Kim D-H, Sarbassov DD, Ali SM et al (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. *Cell* 110:163–175
- Kim D-H, Sarbassov DD, Ali SM et al (2003) GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. *Mol Cell Biol* 23:895–904
- Kimball SR (1999) Eukaryotic initiation factor eIF2. *Int J Biochem Cell Biol* 31:25–29

- Kimball SR, Horetsky RL, Jefferson LS (1998) Implication of eIF2B rather than eIF4E in the regulation of global protein synthesis by amino acids in L6 myoblasts. *J Biol Chem* 273:30945–30953
- Konopka AR, Douglass MD, Kaminsky LA, Jemiolo B, Trappe TA, Trappe S, Harber MP (2010) Molecular adaptations to aerobic exercise training in skeletal muscle of older women. *J Gerontol A Biol Sci Med Sci* 65A:1201–1207
- Koopman R, Saris WH, Wagenmakers AJ, van Loon LJ (2007) Nutritional interventions to promote positive muscle protein synthesis. *Sports Med* 37:895–906
- Kostyak JC, Kimball SR, Jefferson LS, Farrell PA (2001) Severe diabetes inhibits resistance exercise-induced increase in eukaryotic initiation factor 2B activity. *J Appl Physiol* 91:79–84
- Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, Roth RA (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. *J Biol Chem* 278:10189–10194
- Kraemer WJ, Nindl BC, Ratamess NA et al (2004) Changes in muscle hypertrophy in women with periodized resistance training. *Med Sci Sports Exerc* 36:697–708
- Krieg J, Hofsteenge J, Thomas G (1988) Identification of the 40 S ribosomal protein S6 phosphorylation sites induced by cycloheximide. *J Biol Chem* 263:11473–11477
- Kruppa J, Clemens MJ (1984) Differential kinetics of changes in the state of phosphorylation of ribosomal protein S6 and in the rate of protein synthesis in MPC 11 cells during tonicity shifts. *EMBO J* 3:95–100
- Kubica N, Kimball SR, Jefferson LS, Farrell PA (2004) Alterations in the expression of mRNAs and proteins that code for species relevant to eIF2B activity after an acute bout of resistance exercise. *J Appl Physiol* 96:679–687
- Kubica N, Bolster DR, Farrell PA, Kimball SR, Jefferson LS (2005) Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2B epsilon mRNA in a mammalian target of rapamycin-dependent manner. *J Biol Chem* 280:7570–7580
- Kubica N, Crispino JL, Gallagher JW, Kimball SR, Jefferson LS (2008) Activation of the mammalian target of rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2B[epsilon] mRNA translation and protein synthesis. *Int J Biochem Cell Biol* 40:2522–2533
- Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. *Nature* 358:70–73
- Lamming DW, Ye L, Katagisto P et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science* 335:1638–1643
- Latres E, Amini AR, Amini AA et al (2005) Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. *J Biol Chem* 280:2737–2744
- Lee NKL, MacLean HE (2011) Polyamines, androgens and skeletal muscle hypertrophy. *J Cell Physiol* 126:1453–1460
- Lee RC, Wang Z, Heo M, Ross R, Janssen I, Heymsfield SB (2000) Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. *Am J Clin Nutr* 72:796–803
- Leger B, Cartoni R, Praz M et al (2006) Akt signalling through GSK-3beta; mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. *J Physiol* 576:923–933
- Loewith R, Jacinto E, Wullschlegel S et al (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. *Mol Cell* 10:457–468
- Loh PG, Yang H-S, Walsh MA et al (2009) Structural basis for translational inhibition by the tumour suppressor Pdc4. *EMBO J* 28:274–285
- Long X, Ortiz-Vega S, Lin Y, Avruch J (2005) Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. *J Biol Chem* 280:23433–23436
- Lovell DI, Cuneo R, Gass GC (2010) Can aerobic training improve muscle strength and power in older men? *J Aging Phys Act* 18:14–26

- Lynch GS (2004) Tackling Australia's future health problems: developing strategies to combat sarcopenia—age-related muscle wasting and weakness. *Intern Med J* 34:294–296
- Lynch GS, Ryall JG (2008) Role of β -adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. *Physiol Rev* 88:729–767
- Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. *Cell* 121:179–193
- MacDougall JD, Gibala MJ, Tamopolsky MA, MacDonald JR, Interisano SA, Yarasheski KE (1995) The time course for elevated muscle protein synthesis following heavy resistance exercise. *Can J Appl Physiol* 20:480–486
- MacKenzie MG, Hamilton DL, Murray JT, Baar K (2007) mVps34 is activated by an acute bout of resistance exercise. *Biochem Soc Trans* 35:1314–1316
- Mahoney SJ, Dempsey JM, Blenis J (2009) Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation. *Prog Mol Biol Transl Sci* 90C:53–107
- Marino JS, Tausch BJ, Dearth CL et al (2008) β 2-integrins contribute to skeletal muscle hypertrophy in mice. *Am J Physiol Cell Physiol* 295:C1026–C1036
- Martineau LC, Gardiner PF (2001) Insight into skeletal muscle mechanotransduction: MAPK activation is quantitatively related to tension. *J Appl Physiol* 91:693–702
- Mascher H, Andersson H, Nilsson PA, Ekblom B, Blomstrand E (2007) Changes in signalling pathways regulating protein synthesis in human muscle in the recovery period after endurance exercise. *Acta Physiol* 191:67–75
- Mascher H, Ekblom B, Rooyackers O, Blomstrand E (2011) Enhanced rates of muscle protein synthesis and elevated mTOR signalling following endurance exercise in human subjects. *Acta Physiol* 202:175–184
- Matheny RW Jr, Nindl BC, Adamo ML (2010) Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. *Endocrinology* 151:865–875
- Mayer C, Grummt I (2006) Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. *Oncogene* 25:6384–6391
- Mayhew DL, Hornberger TA, Lincoln HC, Bamman MM (2011) Eukaryotic initiation factor 2B (epsilon) (eIF2B{epsilon}) induces cap-dependent translation and skeletal muscle hypertrophy. *J Physiol* 589:3023–3037
- McCall GE, Byrnes WC, Dickinson A, Pattany PM, Fleck SJ (1996) Muscle fiber hypertrophy, hyperplasia, and capillary density in college men after resistance training. *J Appl Physiol* 81:2004–2012
- McCarthy JJ (2011) The MyomiR network in skeletal muscle plasticity. *Exerc Sport Sci Rev* 39:150–154
- McCarthy JJ, Esser KA (2007) Counterpoint: satellite cell addition is not obligatory for skeletal muscle hypertrophy. *J Appl Physiol* 103:1100–1102; discussion 1102–1103
- McCarthy JJ, Mula J, Miyazaki M et al (2011) Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. *Development* 138:3657–3666
- McConnell GK, Rattigan S, Lee-Young RS, Wadley GD, Merry TL (2012) Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. *Am J Physiol – Endocrinol Metab* 303:E301–E307
- McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G (1999) Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. *J Physiol* 516:583–592
- McPhee JS, Williams AG, Degens H, Jones DA (2010) Inter-individual variability in adaptation of the leg muscles following a standardised endurance training programme in young women. *Eur J Appl Physiol* 109:1111–1118
- Meyuhas O, Dreazen A (2009) Ribosomal protein S6 kinase from TOP mRNAs to cell size. *Prog Mol Biol Transl Sci* 90C:109–153
- Mieulet V, Roceri M, Espeillac C et al (2007) S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. *Am J Physiol Cell Physiol* 293:C712–C722

- Miller BF, Olesen JL, Hansen M et al (2005) Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. *J Physiol* 567:1021–1033
- Miyazaki M, McCarthy JJ, Fedele MJ, Esser KA (2011) Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling. *J Physiol* 589:1831–1846
- Monier S, Le Cam A, Le Marchand-Brustel Y (1983) Insulin and insulin-like growth factor I. Effects on protein synthesis in isolated muscles from lean and goldthioglucose-obese mice. *Diabetes* 32:392–397
- Montine KS, Henshaw EC (1990) TPA stimulates S6 phosphorylation but not protein synthesis in Ehrlich cells. *Biochem Biophys Res Commun* 166:1340–1345
- Moore CEJ, Xie J, Gomez E, Herbert TP (2009) Identification of cAMP-dependent kinase as a third in vivo ribosomal protein S6 kinase in pancreatic β -cells. *J Mol Biol* 389:480–494
- Morrison DK (2012) MAP kinase pathways. *Cold Spring Harb Perspect Biol* 4:pii: a011254
- Moss T, Langlois F, Gagnon-Kugler T, Stefanovsky V (2007) A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis. *Cell Mol Life Sci* 64:29–49
- Musaro A, McCullagh K, Paul A et al (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. *Nat Genet* 27:195–200
- Nakai N, Kawano F, Oke Y, Nomura S, Ohira T, Fujita R, Ohira Y (2010) Mechanical stretch activates signaling events for protein translation initiation and elongation in C2C12 myoblasts. *Mol Cells* 30:513–518
- Neff F, Flores-Dominguez D, Ryan DP et al (2013) Rapamycin extends murine lifespan but has limited effects on aging. *J Clin Invest* 123:3272–3291
- Nojima H, Tokunaga C, Eguchi S et al (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. *J Biol Chem* 278:15461–15464
- Novak ML, Billich W, Smith SM, Sukhija KB, McLoughlin TJ, Hornberger TA, Koh TJ (2009) COX-2 inhibitor reduces skeletal muscle hypertrophy in mice. *Am J Physiol Regul Integr Comp Physiol* 296:R1132–R1139
- Nygard O, Nilsson L (1990) Translational dynamics. *Eur J Biochem* 191:1–17
- O'Connor RS, Pavlath GK (2007) Point:counterpoint: satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. *J Appl Physiol* 103:1099–1100
- O'Connor RS, Pavlath GK, McCarthy JJ, Esser KA (2007) Last word on point:counterpoint: satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. *J Appl Physiol* 103:1107
- O'Neil TK, Duffy LR, Frey JW, Hornberger TA (2009) The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. *J Physiol* 587:3691–3701
- Ogasawara R, Sato K, Higashida K, Nakazato K, Fujita S (2013) Ursolic acid stimulates mTORC1 signaling after resistance exercise in rat skeletal muscle. *Am J Physiol Endocrinol Metab* 305:E760–E765
- Ohanna M, Sobering AK, Lapointe T et al (2005) Atrophy of S6K1(–/–) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. *Nat Cell Biol* 7:286–294
- Oshiro N, Yoshino K-I, Hidayat S et al (2004) Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. *Genes Cells* 9:359–366
- Oshiro N, Takahashi R, Yoshino K-I et al (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. *J Biol Chem* 282:20329–20339
- Overgaard K, Fredsted A, Hyldal A, Ingemann-Hansen T, Gissel H, Clausen T (2004) Effects of running distance and training on Ca^{2+} content and damage in human muscle. *Med Sci Sports Exerc* 36:821–829
- Park I-H, Bachmann R, Shirazi H, Chen J (2002) Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. *J Biol Chem* 277:31423–31429
- Park IH, Erbay E, Nuzzi P, Chen J (2005) Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1. *Exp Cell Res* 309:211–219

- Parkington JD, Siebert AP, LeBrasseur NK, Fielding RA (2003) Differential activation of mTOR signaling by contractile activity in skeletal muscle. *Am J Physiol Regul Integr Comp Physiol* 285:R1086–R1090
- Pause A, Belsham GJ, Gingras A-C, Donze O, Lin T-A, Lawrence JC, Sonenberg N (1994) Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. *Nature* 371:762–767
- Pearce LR, Huang X, Boudeau J et al (2007) Identification of rictor as a novel rictor-binding component of mTOR complex-2. *Biochem J* 405:513–522
- Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, Thomas G (1995) The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. *EMBO J* 14:5279–5287
- Pende M, Um SH, Mieulet V et al (2004) S6K1^{-/-}/S6K2^{-/-} mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. *Mol Cell Biol* 24:3112–3124
- Perrone CE, Fenwick-Smith D, Vandenberg HH (1995) Collagen and stretch modulate autocrine secretion of insulin-like growth factor-1 and insulin-like growth factor binding proteins from differentiated skeletal muscle cells. *J Biol Chem* 270:2099–2106
- Perry J, Kleckner N (2003) The ATRs, ATMs, and TORs are giant HEAT repeat proteins. *Cell* 112:151–155
- Peterson RT, Desai BN, Hardwick JS, Schreiber SL (1999) Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12–rapamycin-associated protein. *Proc Natl Acad Sci U S A* 96:4438–4442
- Peterson TR, Laplante M, Thoreen CC et al (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* 137:873–886
- Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR (1997) Mixed muscle protein synthesis and breakdown after resistance exercise in humans. *Am J Physiol* 273:E99–E107
- Phillips BE, Hill DS, Atherton PJ (2012) Regulation of muscle protein synthesis in humans. *Curr Opin Clin Nutr Metab Care* 15:58–63
- Philp A, Hamilton DL, Baar K (2011) Signals mediating skeletal muscle remodeling by resistance exercise: PI3-kinase independent activation of mTORC1. *J Appl Physiol* 110:561–568
- Piccirillo R, Demontis F, Perrimon N, Goldberg AL (2013) Mechanisms of muscle growth and atrophy in mammals and *Drosophila*. *Dev Dyn*, in press, doi: 10.1002/dvdy.24036:n/a-n/a
- Pikosky MA, Gaine PC, Martin WF, Grabarz KC, Ferrando AA, Wolfe RR, Rodriguez NR (2006) Aerobic exercise training increases skeletal muscle protein turnover in healthy adults at rest. *J Nutr* 136:379–383
- Poulin F, Gingras A-C, Olsen H, Chevalier S, Sonenberg N (1998) 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. *J Biol Chem* 273:14002–14007
- Powers SK, Jackson MJ (2008) Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. *Physiol Rev* 88:1243–1276
- Price DJ, Gunsalus JR, Avruch J (1990) Insulin activates a 70-kDa S6 kinase through serine/threonine-specific phosphorylation of the enzyme polypeptide. *Proc Natl Acad Sci U S A* 87:7944–7948
- Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. *Science* 257:973–977
- Proud CG (2005) eIF2 and the control of cell physiology. *Semin Cell Dev Biol* 16:3–12
- Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G (1998) Phosphorylation and activation of p70s6k by PDK1. *Science* 279:707–710
- Ramirez-Rangel I, Bracho-Valdes I, Vazquez-Macias A, Carretero-Ortega J, Reyes-Cruz G, Vazquez-Prado J (2011) Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57. *Mol Cell Biol* 31:1657–1671
- Reidy PT, Konopka AR, Hinkley JM, Udem MK, Harber MP (2013) The effect of feeding during recovery from aerobic exercise on skeletal muscle intracellular signaling. *Int J Sport Nutr Exerc Metab*, in press

- Rommel C, Bodine SC, Clarke BA et al (2001) Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nat Cell Biol* 3:1009–1013
- Rose AJ, Richter EA (2009) Regulatory mechanisms of skeletal muscle protein turnover during exercise. *J Appl Physiol* 106:1702–1711
- Rosner M, Hengstschläger M (2008) Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. *Hum Mol Genet* 17:2934–2948
- Ross A, Leveritt M (2001) Long-term metabolic and skeletal muscle adaptations to short-sprint training: implications for sprint training and tapering. *Sports Med* 31:1063–1082
- Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. *Proc Natl Acad Sci U S A* 101:13489–13494
- Roux PP, Shahbazian D, Vu H et al (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates Cap-dependent translation. *J Biol Chem* 282:14056–14064
- Rundqvist HC, Lilja MR, Rooyackers O, Odrzywol K, Murray JT, Esbjornsson M, Jansson E (2013) Nutrient ingestion increased mTOR signaling, but not hVps34 activity in human skeletal muscle after sprint exercise. *Physiol Rep* 1:e00076
- Ruvinsky I, Sharon N, Lerer T et al (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. *Genes Dev* 19:2199–2211
- Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. *Cell* 78:35–43
- Sabatini DM, Barrow RK, Blackshaw S et al (1999) Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling. *Science* 284:1161–1164
- Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT (1995) Isolation of a protein target of the FKBP12–rapamycin complex in mammalian cells. *J Biol Chem* 270:815–822
- Saito K, Araki Y, Kontani K, Nishina H, Katada T (2005) Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin. *J Biochem* 137:423–430
- Sancak Y, Thoreen CC, Peterson TR et al (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. *Mol Cell* 25:903–915
- Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. *Science* 320:1496–1501
- Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM (2010) Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* 141:290–303
- Sandri M (2008) Signaling in muscle atrophy and hypertrophy. *Physiology* 23:160–170
- Sandri M (2013) Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. *Int J Biochem Cell Biol* 45:2121–2129
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* 307:1098–1101
- Sarbassov DD, Ali SM, Sengupta S et al (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell* 22:159–168
- Sasai N, Agata N, Inoue-Miyazu M, Kawakami K, Kobayashi K, Sokabe M, Hayakawa K (2010) Involvement of PI3K/Akt/TOR pathway in stretch-induced hypertrophy of myotubes. *Muscle Nerve* 41:100–106
- Sato T, Nakashima A, Guo L, Tamanoi F (2009) Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. *J Biol Chem* 284:12783–12791

- Sato T, Hongu T, Sakamoto M, Funakoshi Y, Kanaho Y (2013) Molecular mechanisms of N-formyl-methionyl-leucyl-phenylalanine-induced superoxide generation and degranulation in mouse neutrophils: phospholipase D is dispensable. *Mol Cell Biol* 33:136–145
- Schalm SS, Blenis J (2002) Identification of a conserved motif required for mTOR signaling. *Curr Biol* 12:632–639
- Schalm SS, Fingar DC, Sabatini DM, Blenis J (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. *Curr Biol* 13:797–806
- Schiaffino S, Mammucari C (2011) Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. *Skeletal Muscle* 1:4
- Schieke SM, Phillips D, McCoy JP Jr, Aponte AM, Shen R-F, Balaban RS, Finkel T (2006) The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. *J Biol Chem* 281:27643–27652
- Seene T, Kaasik P, Alev K (2011) Muscle protein turnover in endurance training: a review. *Int J Sports Med* 32:905–911
- Seguin R, Nelson ME (2003) The benefits of strength training for older adults. *Am J Prev Med* 25:141–149
- Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. *Transplant Proc* 35:S7–S14
- Sehgal SN, Baker H, Vezina C (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. *J Antibiot (Tokyo)* 28:727–732
- Shahbazian D, Roux PP, Mieulet V et al (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. *EMBO J* 25:2781–2791
- Sheffield-Moore M, Yeckel CW, Volpi E et al (2004) Postexercise protein metabolism in older and younger men following moderate-intensity aerobic exercise. *Am J Physiol Endocrinol Metab* 287:E513–E522
- Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC (1998) Disruption of the p70 (s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. *EMBO J* 17:6649–6659
- Shor B, Wu J, Shakey Q, Toral-Barza L, Shi C, Follettie M, Yu K (2010) Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. *J Biol Chem* 285:15380–15392
- Short KR, Vittone JL, Bigelow ML, Proctor DN, Nair KS (2004) Age and aerobic exercise training effects on whole body and muscle protein metabolism. *Am J Physiol Endocrinol Metab* 286:E92–E101
- Smith CJ, Wejksnora PJ, Warner JR, Rubin CS, Rosen OM (1979) Insulin-stimulated protein phosphorylation in 3T3-L1 preadipocytes. *Proc Natl Acad Sci U S A* 76:2725–2729
- Smith LW, Smith JD, Criswell DS (2002) Involvement of nitric oxide synthase in skeletal muscle adaptation to chronic overload. *J Appl Physiol* 92:2005–2011
- Soltow QA, Betters JL, Sellman JE, Lira VA, Long JH, Criswell DS (2006) Ibuprofen inhibits skeletal muscle hypertrophy in rats. *Med Sci Sports Exerc* 38:840–846
- Spangenburg EE, Le Roith D, Ward CW, Bodine SC (2008) A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. *J Physiol* 586:283–291
- Srikanthan P, Karlamangla AS (2011) Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from The Third National Health and Nutrition Examination Survey. *J Clin Endocrinol Metab* 96:2898–2903
- Stambolic V, Woodgett JR (1994) Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. *Biochem J* 303(Pt 3):701–704
- Staron RS, Malicky ES, Leonardi MJ, Falkel JE, Hagerman FC, Dudley GA (1990) Muscle hypertrophy and fast fiber type conversions in heavy resistance-trained women. *Eur J Appl Physiol Occup Physiol* 60:71–79
- Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T (2001) An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. *Mol Cell* 8:1063–1073

- Stolovich M, Tang H, Hornstein E et al (2002) Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. *Mol Cell Biol* 22:8101–8113
- Su W, Yeku O, Olepu S et al (2009) 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. *Mol Pharmacol* 75:437–446
- Suzuki C, Garces RG, Edmonds KA, Hiller S, Hyberts SG, Marintchev A, Wagner G (2008) PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. *Proc Natl Acad Sci U S A* 105:3274–3279
- Tang H, Hornstein E, Stolovich M et al (2001) Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by Rapamycin, and is independent of S6K1 and rpS6 phosphorylation. *Mol Cell Biol* 21:8671–8683
- Tang W, Yuan J, Chen X et al (2006) Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway. *J Biochem Mol Biol* 39:626–635
- Tannerstedt J, Apro W, Blomstrand E (2009) Maximal lengthening contractions induce different signaling responses in the type I and type II fibers of human skeletal muscle. *J Appl Physiol* 106:1412–1418
- Tas PWL, Martini OHW (1987) Are highly phosphorylated 40-S subunits preferentially utilized during protein synthesis in a cell-free system from HeLa cells? *Eur J Biochem* 163:561–567
- Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, tuberlin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. *Curr Biol* 13:1259–1268
- Terzis G, Georgiadis G, Stratakis G et al (2008) Resistance exercise-induced increase in muscle mass correlates with p70S6 kinase phosphorylation in human subjects. *Eur J Appl Physiol* 102:145–152
- Thalacker-Mercer A, Stec M, Cui X, Cross J, Windham S, Bamman M (2013) Cluster analysis reveals differential transcript profiles associated with resistance training-induced human skeletal muscle hypertrophy. *Physiol Genomics* 45:499–507
- Thomson DM, Gordon SE (2006) Impaired overload-induced muscle growth is associated with diminished translational signalling in aged rat fast-twitch skeletal muscle. *J Physiol* 574:291–305
- Thomson DM, Fick CA, Gordon SE (2008) AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions. *J Appl Physiol* 104:625–632
- Thomson DM, Brown JD, Fillmore N et al (2009) AMP-activated protein kinase response to contractions and treatment with the AMPK activator AICAR in young adult and old skeletal muscle. *J Physiol* 587:2077–2086
- Thoreen CC, Sabatini DM (2009) Rapamycin inhibits mTORC1, but not completely. *Autophagy* 5:725–726
- Thoreen CC, Kang SA, Chang JW et al (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *J Biol Chem* 284:8023–8032
- Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature* 485:109–113
- Topisirovic I, Svitkin YV, Sonenberg N, Shatkin AJ (2011) Cap and cap-binding proteins in the control of gene expression. *Wiley Interdiscip Rev: RNA* 2:277–298
- Trappe TA, White F, Lambert CP, Cesar D, Hellerstein M, Evans WJ (2002) Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. *Am J Physiol Endocrinol Metab* 282:E551–E556
- Tsang CK, Liu H, Zheng XFS (2010) MTOR binds to the promoters of RNA polymerase I- and III-transcribed genes. *Cell Cycle* 9:953–957

- Tuckow AP, Vary TC, Kimball SR, Jefferson LS (2010) Ectopic expression of eIF2B (varepsilon) in rat skeletal muscle rescues the sepsis-induced reduction in guanine nucleotide exchange activity and protein synthesis. *Am J Physiol Endocrinol Metab* 299:E241–E248
- Uchiumi T, Kikuchi M, Ogata K (1986) Cross-linking study on protein neighborhoods at the subunit interface of rat liver ribosomes with 2-iminothiolane. *J Biol Chem* 261:9663–9667
- Vandenberg HH (1987) Motion into mass: how does tension stimulate muscle growth? *Med Sci Sports Exerc* 19:S142–S149
- Verney J, Kadi F, Charifi N et al (2008) Effects of combined lower body endurance and upper body resistance training on the satellite cell pool in elderly subjects. *Muscle Nerve* 38:1147–1154
- Veveřka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, Carr MD (2008) Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. *Oncogene* 27:585–595
- Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. *J Antibiot (Tokyo)* 28:721–726
- von Manteuffel SR, Gingras AC, Ming XF, Sonenberg N, Thomas G (1996) 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. *Proc Natl Acad Sci U S A* 93:4076–4080
- von Manteuffel SR, Dennis PB, Pullen N, Gingras AC, Sonenberg N, Thomas G (1997) The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. *Mol Cell Biol* 17:5426–5436
- Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG (2001) Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase. *EMBO J* 20:4370–4379
- Wang X, Devaiah SP, Zhang W, Welte R (2006) Signaling functions of phosphatidic acid. *Prog Lipid Res* 45:250–278
- Wang L, Harris TE, Roth RA, Lawrence JC Jr (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. *J Biol Chem* 282:20036–20044
- Wang L, Harris TE, Lawrence JC Jr (2008) Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. *J Biol Chem* 283:15619–15627
- Wang L, Mascher H, Psilander N, Blomstrand E, Sahlin K (2011) Resistance exercise enhances the molecular signaling of mitochondrial biogenesis induced by endurance exercise in human skeletal muscle. *J Appl Physiol* 111:1335–1344
- Welle S, Bhatt K, Thornton CA (1999) Stimulation of myofibrillar synthesis by exercise is mediated by more efficient translation of mRNA. *J Appl Physiol* 86:1220–1225
- Welsh GI, Miyamoto S, Price NT, Safer B, Proud CG (1996) T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. *J Biol Chem* 271:11410–11413
- West DW, Kujbida GW, Moore DR et al (2009) Resistance exercise-induced increases in putative anabolic hormones do not enhance muscle protein synthesis or intracellular signalling in young men. *J Physiol* 587:5239–5247
- White JP, Reecy JM, Washington TA et al (2009) Overload-induced skeletal muscle extracellular matrix remodelling and myofibre growth in mice lacking IL-6. *Acta Physiol* 197:321–332
- Wilkinson SB, Phillips SM, Atherton PJ, Patel R, Yarasheski KE, Tarnopolsky MA, Rennie MJ (2008) Differential effects of resistance and endurance exercise in the fed state on signalling molecule phosphorylation and protein synthesis in human muscle. *J Physiol* 586:3701–3717
- Witard OC, Tieland M, Beelen M, Tipton KD, van Loon LJ, Koopman R (2009) Resistance exercise increases postprandial muscle protein synthesis in humans. *Med Sci Sports Exerc* 41:144–154
- Withers DJ, Ouwens DM, Nave BT et al (1997) Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells. *Biochem Biophys Res Commun* 241:704–709

- Witkowski S, Lovering RM, Spangenburg EE (2010) High-frequency electrically stimulated skeletal muscle contractions increase p70s6k phosphorylation independent of known IGF-I sensitive signaling pathways. *FEBS Lett* 584:2891–2895
- Xu L, Salloum D, Medlin PS, Saqqa M, Yellen P, Perrella B, Foster DA (2011) Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). *J Biol Chem* 286:25477–25486
- Yan Z, Biggs RB, Booth FW (1993) Insulin-like growth factor immunoreactivity increases in muscle after acute eccentric contractions. *J Appl Physiol* 74:410–414
- Yanase Y, Carvou N, Frohman MA, Cockcroft S (2010) Reversible bleb formation in mast cells stimulated with antigen is Ca²⁺/calmodulin-dependent and bleb size is regulated by ARF6. *Biochem J* 425:179–193
- Yang S, Alnaqeeb M, Simpson H, Goldspink G (1996) Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. *J Muscle Res Cell Motil* 17:487–495
- Yang D, Brunn GJ, Lawrence JC Jr (1999) Mutational analysis of sites in the translational regulator, PHAS-I, that are selectively phosphorylated by mTOR. *FEBS Lett* 453:387–390
- Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP (2013) mTOR kinase structure, mechanism and regulation. *Nature* 497:217–223
- Yoon M-S, Du G, Backer JM, Frohman MA, Chen J (2011) Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. *J Cell Biol* 195:435–447
- You JS, Frey JW, Hornberger TA (2012) Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid. *PLoS One* 7:e47258
- You J-S, Lincoln HC, Kim C-R, Frey JW, Goodman CA, Zhong X-P, Hornberger TA (2013) The role of diacylglycerol kinase ζ and phosphatidic acid in the mechanical activation of mammalian target of rapamycin (mTOR) signaling and skeletal muscle hypertrophy. *J Biol Chem*, in press, doi: 10.1074/jbc.M113.531392
- Yu K, Toral-Barza L, Shi C et al (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. *Cancer Res* 69:6232–6240
- Zargar S, Moreira TS, Samimi-Seisan H et al (2011) Skeletal muscle protein synthesis and the abundance of the mRNA translation initiation repressor PDCD4 are inversely regulated by fasting and refeeding in rats. *Am J Physiol Endocrinol Metab* 300:E986–E992
- Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. *Nat Cell Biol* 5:578–581
- Zhang Y, Bokov A, Gelfond J et al (2013) Rapamycin extends life and health in C57BL/6 mice. *J Gerontol A Biol Sci Med Sci*, in press, doi: 10.1093/gerona/glt056
- Zhao J, Yuan X, Frödin M, Grummt I (2003) ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. *Mol Cell* 11:405–413
- Zhao Y, Xiong X, Sun Y (2011) DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF (β TrCP) E3 ubiquitin ligase and regulates survival and autophagy. *Mol Cell* 44:304–316
- Zhao K, Zhou H, Zhao X et al (2012) Phosphatidic acid mediates the targeting of tBid to induce lysosomal membrane permeabilization and apoptosis. *J Lipid Res* 53:2102–2114